Supplementary Material

Conserved and species-specific transcription factor co-binding patterns drive divergent gene regulation in human and mouse

Adam G. Diehl¹, Alan P. Boyle^{1,2*}

¹Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA ²Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA

List of Supplementary Items

Effects of removing patterns present in 10,000 random data	2
	3
	3
	4
	5
	-
the two largest cohesin-related grammatical patterns from the MCKG	
class.	
Conserved PhastCons scores cluster near ChIP-seq peak summits in	6
	_
· · ·	7
v 1	8
	0
	10
positional class.	
Cell-specificity of chromatin states is not affected by inclusion	11
thresholds.	
	14
Identification of chromHMM annotations used in this project.	16
Identification of DNase-seq datasets used in this project.	16
Identification of RNA-seq datasetsused in this project.	16
Orthology statistics and PhastCons element intersections for human	17
•	. –
	17
	18
	10
	19
	27
	28
	28
	permutations. Grammatical pattern distributions within positional classes. Gain/loss phylogeny. Aggregate grammatical classes explained. Frequency histograms of functional annotations associated with regulatory function in six aggregate grammatical classes after excluding the two largest cohesin-related grammatical patterns from the MCKG class. Conserved PhastCons scores cluster near ChIP-seq peak summits in all fractions of the dataset. Grammatical patterns predict matched chromatin states more accurately than positional conservation of chromatin states predicts matched grammatical patterns. Graphical definition of counting conventions used in chromatin state heatmaps. Chromatin state overlaps in individual cell types by grammatical and positional class. Cell-specificity of chromatin states is not affected by inclusion thresholds. Identification of transcription factor binding datasets used in this project. Identification of DNase-seq datasets used in this project. Identification of RNA-seq datasetsused in this project.




Figure S1. Effects of removing patterns present in 10,000 random data permutations.

(A) Distribution of p-values relative to grammatical pattern lengths in the unfiltered dataset shows no apparent difference between long and short patterns at either end of the p-value spectrum. (B) Length distributions of grammatical patterns in the unfiltered dataset, filtered, and discarded fractions of the dataset. Although the bulk of filtered patterns contained between 2 and 5 factors, removing these patterns caused a mean shift of only 2 units between the unfiltered and filtered datasets, with no effect on maximum and minimum pattern lengths. (C-D) Venn diagrams show the segmentation of regulatory space into 15 possible grammatical and positional classes in the unfiltered dataset (C) and filtered dataset(D). The first letter of each cell type was used to construct a class label for each cell in the diagrams. These labels describe the cell-specificity of the corresponding grammatical patterns and positionally-conserved loci. Each segment in the Venn diagrams is labelled with its grammatical class and the number of grammatical patterns, 86% of which are shared between human and mouse. (D) The filtered dataset contains a total of 780 grammatical patterns, 76% of which are shared between human and mouse.




Figure S2. Grammatical pattern distributions within positional classes.

Each column in the matrix represents a combination of matched or mismatched patterns between sequences bound at the same locus. Column headings indicate the positional class represented by a set of columns and the number below each column represents the total number of CRMs within the subset. Cells with matching colors in a column share the same grammatical pattern while cells with mismatched colors are occupied by different grammatical patterns. Green cells indicate sequences which are physically present, but are not occupied in the given cell type. Grey cells indicate sequence es which are physically absent in the given species as a result of sequence gain or loss. Orange hues indicate species-specific sequence gains and purple hues indicate sequence losses in the other species, based on phylogenetic maximum parsimony prediction using three outgroup species.




Figure S3. Gain/loss phylogeny.

Phylogenetic tree describing evolutionary relationships between human, mouse and the outgroup species horse, dog and elephant, used in assigning non-orthologous CRMs as species-specific gains or losses.

Aggregate Grammatical Classes




Figure S4. Aggregate grammatical classes explained.

Grammatical classes were aggregated into six species-specific and tissue-specific aggregate grammatical classes to facilitate further analysis of functional specificity.





Figure S5. Frequency histograms of functional annotations associated with regulatory function in six aggregate grammatical classes after excluding the two largest cohesin-related grammatical patterns from the MCKG class.

(A) Intersection with DNasel Hypersensitive Sites (B) Intersection with ChromHmm active chromatin states. (C) Intersection with PhastCons elements.



Distance from ChIP-seq Peak Summit

Figure S6. Conserved PhastCons scores cluster near ChIP-seq peak summits in all fractions of the dataset.

PhastCons scores within 400bp windows centered over ChIP-seq peak summits from 1000 randomly-selected CRMs classified as orthologs, losses, and gains in Human and Mouse. Clustering of scores approaching 1 centered around ChIP-seq peak summits suggests significant contributions of occupied TFBS to overall conservation in many CRMs. Scores approaching 1 in more distant foci may correspond with additional TFBSs for which we lack ChIP-seq data, TFBSs occupied only in other cell types, or other classes of functional sequence not annotated in the current study. Longer stretches of high PhastCons scores, concentrated among the top rows of all groups, likely reflect the "smoothing" effect of the PhastCons hidden Markov model over stretches of DNA containing multiple conserved features in close proximity.




Figure S7. Grammatical patterns predict matched chromatin states more accurately than positional conservation of chromatin states predicts matched grammatical patterns.

(A) Fractions of positionally-conserved locus pairs with matched Promoter, Strong Enhancer, or Weak Enhancer chromatin states and/or grammatical patterns. (B) Fractions of locus pairs within grammatical patterns where the underlying Promoter, Strong Enhancer, or Weak Enhancer chromatin state

also matches. **(C)** Chromatin states within all 77 CRMs CRMs in grammatical pattern 821 (CG gramatical class (M and K). (D) Ten randomly-selected orthologous loci representing positional class CG and containing the promoter state in one or both of C and G. Each block represents a different genomic locus, with individual rows representing the chromatin states observed in the cell type indicated.





Figure S8. Graphical definition of counting conventions used in chromatin state heatmaps. In all panels, a theoretical set of loci or patterns are given with associated data for the promoter chromatin state, and the accompanying heatmap shows the result from the applicable counting procedure. (A) For Fig 4C, counts are aggregated over all grammatical patterns. All grammatical patterns in which >= 50% of CRMs carry a given state are counted in the total column. Among these patterns, In-class: >= 50% of CRMs in cells belonging to the grammatical class carry the state. Outside class: >= 50% of modules from nonmember cells carry the state. (B) For Fig 4D, counts are pooled over all positionally-conserved loci. All loci carrying a given state in >= 1 occupied cell are counted toward the total column. Match: the cell-specificity of chromatin states matches that expected based on the positional class. Mismatch 1: 1 or more cells not included in the positional class carry the given state. Mismatch 2: 1 or more cells within the positonal class lack the given state. (C) For sup fig 5A, counts represent the number of times a chromatin mark was observed in $\geq 50\%$ of peaks form a given pattern within a grammatical class in one cell type given that it was observed in $\geq 50\%$ of peaks from the pattern in a reference cell type. (D) For sup fig 5B, counts represent the number of observations in which a chromatin mark was observed at a positional locus in one cell given that it



P = Promoter SE = Strong Enhancer WE = Weak Enhancer RP = Polycomb Repressed

Figure S9. Chromatin state overlaps in individual cell types by grammatical and positional class.

Heat maps describe the degree of conservation of ChromHMM chromatin states between loci in positional classes and patterns in grammatical classes representing a non-collapsed view of Fig. 4. Shading densities within each cell represent the fraction of loci or patterns that carry the given chromatin state marks. (A) Within grammatical classes, the frequency of overlap for each cell type with a matching module annotation in at least 50% of the loci from all other cell types. This is analogous to "inside class", on a per cell basis, from Fig. 4C. (B) Within positional classes, the frequency of overlap for each cell type with a matching module annotation in at the same loci from all other cell types. This is analogous to "match" on a per cell basis from Fig. 4D.




Figure S10. Cell-specificity of chromatin states is not affected by inclusion thresholds. (A-C) Thresholds for grammatical patterns are arranged in order of increasing stringency. (A) Cell-specificity of chromatin states for grammatical patterns, requiring >= 75% of CRMs within a pattern include a given state. (B) Cell-specificity of chromatin states for grammatical patterns, requiring >= 90% of CRMs within a pattern include a given state. (C) Cell-specificity of chromatin states for grammatical patterns, requiring 100% of CRMs within a pattern include a given state. (D and E) Thresholds for positional classes are arranged in order of decreasing stringency. (D) Cell-specificity of chromatin states for positional classes, allowing up to 1 mismatch before a locus is counted toward either mismatch category. (E) Cell-specificity of chromatin states for positional classes, allowing 1 mismatch for loci occupied in 3 cells and up to 2 mismatches in loci occupied in 4 cells, before a locus is counted toward either mismatch categories.

Table S1.

Identification of transcription factor binding datasets used in this project. All data were obtained from the ENCODE project through encodeproject.org. Accession numbers are provided along with organism, cell, and other relevant information.

Table S2.

Identification of chromHMM annotations used in this project. All data were obtained from the ENCODE project through encodeproject.org. Accession numbers are provided along with organism, cell, and other relevant information.

Table S3.

Identification of DNase-seq datasets used in this project. All data were obtained from the ENCODE project through encodeproject.org. Accession numbers are provided along with organism, cell, and other relevant information.

Table S4.

Identification of RNA-seq datasetsused in this project. All data were obtained from the ENCODE project through encodeproject.org. Accession numbers are provided along with organism, cell, and other relevant information.

Table S5.

Orthology statistics and PhastCons element intersections for human and mouse CRMs and background sequences. Numbers of CRMs/background sequences, percent sequences mappable by bnMapper, and percent of sequences containing <= 1 phastCons element are given for mouse and human sequences for the total dataset, orthologous CRMs, unmapped CRMs (gains and losses combined), species-specific gains and species-specific losses. Odds ratios and p-values were calculated using individual Fisher's Exact tests against matched background sequences. P-values were corrected for multiple testing with the holm method.

Table S6.

Percentage of CRMs and background sequences overlapping DNasel hypersensitive (DHS) sites. The number of human and mouse CRMs in each of six grammatical categories are given along with percentages of CRMs and background sequences within each category overlapping a DHS site(s), for the total dataset, orthologous CRMs, unmapped CRMs (gains and losses combined), species-specific gains and species-specific losses. Odds ratios and p-values were calculated using individual Fisher's Exact tests against matched background sequences. P-values were corrected for multiple testing with the holm method.

Table S7.

Percentage of CRMs and background sequences marked with active chromatin states from ChromHMM [27]. The number of human and mouse CRMs in each of six aggregate grammatical categories are given along with percentages of CRMs and background sequences within each category overlapping regions of the genome assigned to active states (states 1-5) by ChromHMM (see table S1), for the total dataset, orthologous CRMs, unmapped CRMs (gains and losses combined), species-specific gains and species-specific losses. Odds ratios and p-values were calculated using individual Fisher's Exact tests against matched background sequences. P-values were corrected for multiple testing with the holm method.

Table S8.

GWAS Ontology terms and associated functional classifications.

Table S9.

GWAS Ontology term enrichments found within human CRMs pooled across all grammatical patterns. For each term, observed counts were collected by counting the occurrences of each term among CRM-associated GWAS and GWAS-linked SNPs within the human dataset to compute the expected binomial frequency. Each term was counted only once per CRM in cases where a CRM contained multiple SNPs annotated with the same term. All terms in the total dataset with uncorrected p-values <= 0.05 are reported in the table but only those passing a 0.05 threshold after multiple testing correction by the FDR method were retained for further analysis. Immune terms are presented in red text.

Table S10.

GWAS Ontology term enrichments by aggregate grammatical class. CRMs were separated by aggregate grammatical class and binomial enrichment tests for each GWAS Ontology term was performed following the same procedures as for the pooled set. Terms presented in blue text were found only in the analysis of aggregate grammatical classes, but not in the pooled dataset. Immune terms are presented in red text.

Table S11.

GWAS Ontology term enrichments by individual grammatical class. CRMs were separated into individual grammatical classes and binomial enrichment tests for each GWAS Ontology term was performed following the same procedures as for the pooled set. Terms presented in blue text were found only in the analysis of individual grammatical classes, but not in the pooled dataset. Immune terms are presented in red text.

Accession	Species	Cell	TF	Format
ENCSR000ERC	Mouse	CH12	BHLHE40	narrowPeak
ENCSR000DZJ	Human	GM12878	BHLHE40	narrowPeak
ENCSR000EGV	Human	K562	BHLHE40	narrowPeak
ENCSR000ESH	Mouse	MEL	BHLHE40	narrowPeak
ENCSR000EQV	Mouse	CH12	CHD1	narrowPeak
ENCSR000DZE	Human	GM12878	CHD1	narrowPeak
ENCSR000AQD	Human	K562	CHD1	narrowPeak
ENCSR000ESN	Mouse	MEL	CHD1	narrowPeak
ENCSR000ERF	Mouse	CH12	CHD2	narrowPeak
ENCSR000DZR	Human	GM12878	CHD2	narrowPeak
ENCSR000EHD	Human	K562	CHD2	narrowPeak
ENCSR000ETO	Mouse	MEL	CHD2	narrowPeak
ENCSR000ERM	Mouse	CH12	CTCF	narrowPeak
ENCSR000AKB	Human	GM12878	CTCF	narrowPeak
ENCSR000BPJ	Human	K562	CTCF	narrowPeak
ENCSR000ETE	Mouse	MEL	CTCF	narrowPeak
ENCSR000ERU	Mouse	CH12	E2F4	narrowPeak
ENCSR000DYY	Human	GM12878	E2F4	narrowPeak
ENCSR000EWL	Human	K562	E2F4	narrowPeak
ENCSR000ETY	Mouse	MEL	E2F4	narrowPeak
ENCSR293WTN	Mouse	CH12	ELF1	narrowPeak
ENCSR000BMB	Human	GM12878	ELF1	narrowPeak
ENCSR000BMD	Human	K562	ELF1	narrowPeak
ENCSR033OWC	Mouse	MEL	ELF1	narrowPeak
ENCSR000ERI	Mouse	CH12	EP300	narrowPeak
ENCSR000DZD	Human	GM12878	EP300	narrowPeak
ENCSR000EGE	Human	K562	EP300	narrowPeak
ENCSR000ETP	Mouse	MEL	EP300	narrowPeak
ENCSR000ERA	Mouse	CH12	ETS1	narrowPeak
ENCSR000BKA	Human	GM12878	ETS1	narrowPeak
ENCSR000BKQ	Human	K562	ETS1	narrowPeak
ENCSR000ETB	Mouse	MEL	ETS1	narrowPeak
ENCSR000EQS	Mouse	CH12	GABPA	narrowPeak
ENCSR000BGC	Human	GM12878	GABPA	narrowPeak
ENCSR000BLO	Human	K562	GABPA	narrowPeak
ENCSR000ESK	Mouse	MEL	GABPA	narrowPeak
ENCSR000ERR	Mouse	CH12	JUND	narrowPeak
ENCSR000EYV	Human	GM12878	JUND	narrowPeak
ENCSR000EGN	Human	K562	JUND	narrowPeak
ENCSR000ETZ	Mouse	MEL	JUND	narrowPeak
ENCSR000ERB ENCSR000DYV	Mouse	CH12 GM12878	MAFK MAFK	narrowPeak narrowPeak
ENCSR000EGX	Human Human	K562	MAFK	narrowPeak
ENCSR000EJX	Mouse	MEL	MAFK	narrowPeak
ENCSR000ERL	Mouse	CH12	MAX	narrowPeak
ENCSR000DZF	Human	GM12878	MAX	narrowPeak
ENCSR000EFV	Human	K562	MAX	narrowPeak
ENCSR000ETX	Mouse	MEL	MAX	narrowPeak
ENCSR000EQT	Mouse	CH12	MAZ	narrowPeak
ENCSR000DZA	Human	GM12878	MAZ	narrowPeak
ENCSR000EFX	Human	K562	MAZ	narrowPeak
ENCSR000ESL	Mouse	MEL	MAZ	narrowPeak
ENCSR806JZK	Mouse	CH12	MEF2A	narrowPeak
ENCSR000BKB	Human	GM12878	MEF2A	narrowPeak
ENCSR000BNV	Human	K562	MEF2A	narrowPeak
		1	•	1

Accession	Species	Cell	TF	Format
ENCSR867SDZ	Mouse	MEL	MEF2A	narrowPeak
ENCSR000ERE	Mouse	CH12	MXI1	narrowPeak
ENCSR000DZI	Human	GM12878	MXI1	narrowPeak
ENCSR000EGZ	Human	K562	MXI1	narrowPeak
ENCSR000ETN	Mouse	MEL	MXI1	narrowPeak
ENCSR000ERN	Mouse	CH12	MYC	narrowPeak
ENCSR000DKU	Human	GM12878	MYC	narrowPeak
ENCSR000FAZ	Human	K562	MYC	narrowPeak
ENCSR000EUA	Mouse	MEL	MYC	narrowPeak
ENCSR980YXJ	Mouse	CH12	NRF1	narrowPeak
ENCSR000DZO	Human	GM12878	NRF1	narrowPeak
ENCSR000EHH	Human	K562	NRF1	narrowPeak
ENCSR135SWH	Mouse	MEL	NRF1	narrowPeak
ENCSR000ERQ	Mouse	CH12	POLR2A	narrowPeak
ENCSR000BGD	Human	GM12878	POLR2A	narrowPeak
ENCSR000BMR	Human	K562	POLR2A	narrowPeak
ENCSR000EUC	Mouse	MEL	POLR2A	narrowPeak
ENCSR000ERH	Mouse	CH12	POLR2AphosphoS2	narrowPeak
ENCSR000DZK	Human	GM12878	POLR2AphosphoS2	narrowPeak
ENCSR000EGF	Human	K562	POLR2AphosphoS2	narrowPeak
ENCSR000ETM	Mouse	MEL	POLR2AphosphoS2	narrowPeak
ENCSR000ERK	Mouse	CH12	RAD21	narrowPeak
ENCSR000BMY	Human	GM12878	RAD21	narrowPeak
ENCSR000BKV	Human	K562	RAD21	narrowPeak
ENCSR000ETS	Mouse	MEL	RAD21	narrowPeak
ENCSR000EQZ	Mouse	CH12	RCOR1	narrowPeak
ENCSR000DZC	Human	GM12878	RCOR1	narrowPeak
ENCSR000EGG	Human	K562	RCOR1	narrowPeak
ENCSR000ESI	Mouse	MEL	RCOR1	narrowPeak
ENCSR000EQY	Mouse	CH12	SIN3A	narrowPeak
ENCSR000DYX	Human	GM12878	SIN3A	narrowPeak
ENCSR000BLR	Human	K562	SIN3A	narrowPeak
ENCSR000ETC	Mouse	MEL	SIN3A	narrowPeak
ENCSR000ERG	Mouse	CH12	SMC3	narrowPeak
ENCSR000DZP	Human	GM12878	SMC3	narrowPeak
ENCSR000EGW	Human	K562	SMC3	narrowPeak
ENCSR000ETL	Mouse	MEL	SMC3	narrowPeak
ENCSR000ERP	Mouse	CH12	TBP	narrowPeak
ENCSR000DZZ	Human	GM12878	TBP	narrowPeak
ENCSR000EHA	Human	K562	TBP	narrowPeak
ENCSR000EUB	Mouse	MEL	TBP	narrowPeak
ENCSR973SOG	Mouse	CH12	USF1	narrowPeak
ENCSR000BGI	Human	GM12878	USF1	narrowPeak
ENCSR000BKT	Human	K562	USF1	narrowPeak
ENCSR705HGT	Mouse	MEL	USF1	narrowPeak
ENCSR000ERJ	Mouse	CH12	USF2	narrowPeak
ENCSR000DZU	Human	GM12878	USF2	narrowPeak
ENCSR000EHG	Human	K562	USF2	narrowPeak
ENCSR000ETF	Mouse	MEL	USF2	narrowPeak
ENCSR000EQO	Mouse	CH12	ZNF384	narrowPeak
ENCSR000DYP	Human	GM12878	ZNF384	narrowPeak
ENCSR000EFP	Human	K562	ZNF384	narrowPeak
ENCSR000EFF	Mouse	MEL	ZNF384	narrowPeak
	Imouse			nanowi cak

Accession	Species	Cell	format
ENCFF012OHJ	hg19	K562	bigBed
ENCFF836FGC	mm9	MEL	bigBed
ENCFF930VWI	hg19	GM12878	bigBed
ENCFF473FWY	mm9	CH12	bigBed

Table S3

Accession	Species	Cell	Туре	Format
ENCFF001YNS	mm9	CH12	Hotspot	bed
ENCFF001YNT	mm9	CH12	Hotspot	bed
ENCFF001WBD	hg19	K562	Hotspot	bed
ENCFF001WNM	hg19	K562	Hotspot	bed
ENCFF001WNL	hg19	K562	Hotspot	bed
ENCFF001WFR	hg19	GM12878	Hotspot	bed
ENCFF001WFS	hg19	GM12878	Hotspot	bed
ENCFF001YRV	mm9	MEL	Hotspot	bed
ENCFF001YRW	mm9	MEL	Hotspot	bed
ENCFF001YLI	mm9	MEL	Hotspot	bed
ENCFF001YRU	mm9	MEL	Hotspot	bed

Accession	Species	Cell	format	Lab	Sequencer
ENCFF001MFQ	mm9	CH12	fastq	Hardison	Illumina Genome Analyzer IIx
ENCFF001MFP	mm9	CH12	fastq	Hardison	Illumina Genome Analyzer IIx
ENCFF001MKT	mm9	MEL	fastq	Hardison	HiSeq 2000
ENCFF001MKV	mm9	MEL	fastq	Hardison	HiSeq 2001
ENCFF000DWH	hg19	K562	fastq	Wold	Illumina Genome Analyzer (GAI or GAIIx)
ENCFF000DVT	hg19	K562	fastq	Wold	Illumina Genome Analyzer (GAI or GAIIx)
ENCFF000CXI	hg19	GM12878	fastq	Wold	Illumina Genome Analyzer II
ENCFF000CXH	hg19	GM12878	fastq	Wold	Illumina Genome Analyzer II

	ĺ			Orthology		Conser	vation, All M	odules	Conservatio	n, Orthologo	us Modules	Conservatio	on, Unmappe	d Modules	Cor	servation, Ga	ains	Cons	ervation, Los	ses
	Aggregate				Corrected			Corrected			Corrected			Corrected			Corrected			Corrected
	Grammatical Class	# CRMs	% Lifted	Odds Ratio	P-Value	% Int Phast	Odds Ratio	P-Value	% Int Phast	Odds Ratio	P-Value	% Int Phast	Odds Ratio	P-Value	% Int Phast	Odds Ratio	P-Value	% Int Phast	Odds Ratio	P-Value
	Lineage-Specific	3219	79.3%	1.95	2.2E-57	56.3%	2.29	2.0E-116	68.0%	1.80	3.3E-44	11.4%	1.55	<3.0E-300	7.8%	1.37	0.06	32.3%	1.28	0.5
	Mouse-Specific	13385	81.9%	2.30	<3.0E-300	66.2%	3.48	<3.0E-300	73.9%	2.40	<3.0E-300	31.6%	5.54	3.2E-228	27.8%	6.29	3.1E-195	51.8%	2.88	8.1E-21
_	Human-Specific	138	78.3%	1.83	2.8E-03	63.0%	3.03	1.8E-10	72.2%	2.20	2.9E-04	30.0%	5.14	6.1E-04	30.8%	7.25	<3.0E-300	25.0%	0.89	1.0
No	Two-Cell Mixed	2445	88.1%	3.78	1.6E-133	84.2%	9.44	<3.0E-300	88.6%	6.58	5.4E-254	51.4%	12.68	1.7E-83	47.8%	14.94	1.3E-69	64.5%	4.87	5.7E-09
use	Three-Cell	13876	86.8%	3.34	<3.0E-300	81.9%	8.01	<3.0E-300	87.4%	5.90	<3.0E-300	45.2%	9.91	<3.0E-300	41.5%	11.57	4.94e-323	63.4%	4.63	6.7E-36
	MCKG	91992	70.7%	1.23	3.6E-96	53.1%	2.01	<3.0E-300	66.1%	1.65	<3.0E-300	21.7%	3.32	<3.0E-300	19.9%	4.06	<3.0E-300	37.4%	1.60	2.9E-16
	Total	125055	74.3%	1.47	<3.0E-300	58.4%	2.49	<3.0E-300	70.3%	2.01	<3.0E-300	23.8%	3.75	<3.0E-300	21.6%	4.51	<3.0E-300	41.5%	1.90	6.8E-35
	Background	100000	64.9%			36.0%			54.1%			7.7%			5.8%			27.2%		
	Lineage-Specific	3356	76.2%	2.18	2.3E-87	66.0%	3.45	2.3E-258	77.6%	1.47	1.0E-15	28.9%	4.17	3.4E-56	12.3%	3.53	2.8E-09	39.4%	4.00	7.1E-41
	Mouse-Specific	176	72.7%	1.81	7.5E-04	68.8%	3.91	3.8E-18	78.1%	1.52	5.3E-02	43.8%	7.95	5.8E-10	36.0%	14.09	6.8E-07	52.2%	6.72	5.1E-05
-	Human-Specific	8565	83.2%	3.35	<3.0E-300	84.7%	9.86	<3.0E-300	91.4%	4.52	<3.0E-300	51.7%	10.93	<3.0E-300	40.2%	16.82	3.9E-144	58.7%	8.77	4.6E-192
Ľ,	Two-Cell Mixed	6287	80.1%	2.72	1.1E-242	80.9%	7.53	<3.0E-300	88.7%	3.34	4.6E-196	50.1%	10.26	1.4E-285	43.0%	18.93	1.0E-156	55.3%	7.61	3.4E-137
lan	Three-Cell	12687	82.5%	3.21	<3.0E-300	83.8%	9.22	<3.0E-300	90.9%	4.23	<3.0E-300	50.6%	10.47	<3.0E-300	42.4%	18.47	3.9E-234	55.8%	7.76	7.6E-247
	MCKG	53642	74.8%	2.02	<3.0E-300	70.5%	4.26	<3.0E-300	81.2%	1.84	1.0E-293	38.8%	6.49	<3.0E-300	23.6%	7.75	<3.0E-300	47.7%	5.61	<3.0E-300
	Total	84713	77.3%	2.31	<3.0E-300	74.5%	5.21	<3.0E-300	84.3%	2.28	<3.0E-300	41.5%	7.25	<3.0E-300	28.1%	9.79	<3.0E-300	49.5%	6.05	<3.0E-300
	Background	69415	58.8%			36.0%			70.2%			8.9%			3.8%			14.0%		
≥	All	209768	75.5%	1.77	<3.0E-300	64.9%	3.29	<3.0E-300	76.1%	2.10	<3.0E-300	30.4%	4.87	<3.0E-300	22.9%	3.52	<3.0E-300	47.7%	4.62	<3.0E-300
=	Background	169415	62.4%			36.0%			60.3%			8.2%			5.2%			16.5%		

		l		DHS	S All			DHS	Orth			DHS No	onorth			DHS	Gain			DHS	Loss	
	Aggregate					Corrected				Corrected				Corrected				Corrected				Corrected
	Grammatical Class	# CRMs	% DHS	% DHS BG	Odds Ratio	P-Value	%DHS	% DHS BG	Odds Ratio	P-Value	%DHS	% DHS BG	Odds Ratio	P-Value	%DHS	% DHS BG	Odds Ratio	P-Value	%DHS	% DHS BG	Odds Ratio	P-Value
	Lineage-Specific	3219	95.78%	29.64%	53.74	< 1.9E-283	96.56%	4.70%	56.68	< 1.9E-283	92.19%	20.00%	46.88	3.9E-96	91.18%	20.50%	39.71	1.3E-78	97.98%	16.67%	213.28	5.8E-19
	Mouse-Specific	13385	98.31%	26.40%	162.26	< 1.9E-283	98.54%	2.04%	163.54	< 1.9E-283	97.16%	19.59%	139.60	< 1.9E-283	97.02%	19.62%	132.22	< 1.9E-283	97.89%	19.42%	187.60	4.2E-63
Ξ	Human-Specific	138	87.68%	25.00%	20.98	2.1E-24	87.00%	16.46%	19.29	1.8E-17	86.67%	42.86%	7.96	2.7E-02	88.46%	33.33%	13.35	1.2E-02	75.00%	100.00%	0.00	1
Sno	Two-Cell Mixed	2445	99.75%	35.87%	724.79	< 1.9E-283	99.80%	0.28%	783.02	< 1.9E-283	99.31%	27.91%	358.76	9.1E-48	99.12%	30.88%	242.94	4.8E-35	100.00%	16.67%	Inf	3.7E-13
õ	Three-Cell	13876	99.51%	34.41%	384.87	< 1.9E-283	99.59%	0.56%	416.00	< 1.9E-283	98.91%	26.19%	254.12	2.6E-264	99.01%	25.80%	286.39	5.0E-226	98.41%	28.36%	150.62	9.3E-39
	MCKG	91992	80.35%	21.70%	14.76	< 1.9E-283	83.04%	21.96%	15.37	< 1.9E-283	73.58%	15.23%	15.50	< 1.9E-283	72.88%	14.98%	15.24	< 1.9E-283	79.96%	17.49%	18.80	1.9E-239
	Total	125055	85.18%	24.04%	18.16	< 1.9E-283	87.72%	16.21%	19.50	< 1.9E-283	77.44%	16.25%	17.69	< 1.9E-283	76.58%	16.00%	17.17	< 1.9E-283	84.37%	18.40%	23.90	< 1.9E-283
	Lineage-Specific	3356	99.37%	25.58%	456.04	< 1.9E-283	99.57%	0.67%	528.86	< 1.9E-283	98.75%	15.53%	421.97	2.4E-191	97.73%	14.05%	255.68	3.7E-90	99.39%	12.97%	1027.97	9.6E-124
	Mouse-Specific	176	98.86%	26.58%	235.10	1.6E-50	99.21%	1.04%	309.40	1.9E-33	97.92%	7.14%	373.16	4.6E-11	100.00%	0.00%	Inf	2.7E-06	95.65%	16.67%	69.96	5.9E-04
물	Human-Specific	8565	99.31%	34.82%	271.45	< 1.9E-283	99.49%	0.83%	298.47	< 1.9E-283	98.54%	23.76%	215.67	2.7E-259	97.09%	15.23%	183.26	5.9E-145	99.44%	22.85%	591.34	2.4E-175
Ima	Two-Cell Mixed	6287	99.90%	30.57%	2285.62	< 1.9E-283	99.92%	0.12%	2242.03	< 1.9E-283	99.84%	21.35%	2264.44	5.1E-279	99.62%	10.80%	1997.39	2.8E-173	100.00%	24.39%	Inf	1.9E-158
5	Three-Cell	12687	99.68%	34.38%	586.97	< 1.9E-283	99.84%	0.27%	923.32	< 1.9E-283	99.05%	21.27%	384.74	< 1.9E-283	98.02%	13.26%	320.61	3.3E-243	99.71%	20.87%	1228.72	1.9E-283
	MCKG	53642	88.32%	21.19%	28.12	< 1.9E-283	89.66%	15.84%	25.69	< 1.9E-283	84.84%	16.58%	28.13	< 1.9E-283	82.00%	9.52%	43.24	< 1.9E-283	86.49%	16.77%	31.79	< 1.9E-283
_	Total	84713	92.45%	25.09%	36.57	< 1.9E-283	93.57%	9.97%	34.19	< 1.9E-283	89.09%	17.73%	37.82	< 1.9E-283	87.07%	10.49%	57.40	< 1.9E-283	90.30%	17.86%	42.77	< 1.9E-283
	Total All	209768	88.12%	24.47%	22.89	< 1.9E-283	90.19%	13.82%	23.66	< 1.9E-283	81.80%	16.89%	22.11	< 1.9E-283	78.70%	14.09%	22.54	< 1.9E-283	88.95%	17.96%	36.74	< 1.9E-283

				ACS	All			ACS C	Drth			ACS No	north			ACS G	iain			ACS L	.oss	
	Aggregate					Corrected				Corrected				Corrected				Corrected				Corrected
	Grammatical Class	CRMs	% ACS	% ACS BG	Odds Ratio	P-Value	%ACS	% ACS BG	Odds Ratio	P-Value	%ACS	% ACS BG	Odds Ratio	P-Value	%ACS	% ACS BG	Odds Ratio	P-Value	%ACS	% ACS BG	Odds Ratio	P-Value
	Lineage-Specific	3219	77.20%	25.62%	9.82	< 2E-272	80.65%	28.94%	10.23	< 2E-272	61.71%	18.70%	6.99	7.42E-30	59.08%	21.00%	5.42	2.71E-20	76.77%	3.33%	92.18	6.83E-13
_	Mouse-Specific	13385	88.03%	27.70%	19.19	< 2E-272	89.65%	31.15%	19.15	< 2E-272	80.05%	19.59%	16.45	2.46E-186	78.74%	19.97%	14.83	3.13E-148	87.11%	17.48%	31.52	2.51E-40
Mo No	Human-Specific	138	65.22%	35.19%	3.44	3.35E-06	66.00%	40.51%	2.83	3.35E-06	60.00%	0.00%	Inf	7.99E-03	65.38%	0.00%	Inf	5.52E-03	25.00%	0.00%	Inf	1
use	Two-Cell Mixed	2445	94.97%	32.22%	39.65	< 2E-272	95.82%	35.51%	41.56	< 2E-272	88.28%	24.42%	22.98	8.96E-29	87.28%	27.94%	17.43	1.04E-19	91.94%	11.11%	80.34	3.96E-10
	Three-Cell	13876	88.41%	29.80%	17.97	< 2E-272	89.65%	31.94%	18.46	< 2E-272	77.44%	24.83%	10.38	1.04E-93	76.40%	25.80%	9.29	9.84E-73	82.48%	19.40%	19.34	3.49E-22
	MCKG	91992	33.11%	25.18%	1.47	2.35E-272	37.03%	28.35%	1.49	2.35E-272	22.44%	19.91%	1.16	1.51E-06	21.56%	19.84%	1.11	2.56E-03	30.32%	20.57%	1.68	6.76E-08
	Lineage-Specific	3356	92.73%	28.56%	31.89	< 2E-272	93.22%	33.05%	27.81	< 2E-272	90.98%	20.19%	39.67	6.94E-120	87.66%	18.98%	29.95	5.06E-45	93.06%	21.08%	49.56	1.55E-75
-	Mouse-Specific	176	95.45%	32.28%	43.38	4.31E-37	94.44%	35.42%	30.36	4.31E-37	97.92%	21.43%	138.15	2.44E-08	100.00%	25.00%	Inf	7.58E-05	95.65%	16.67%	69.96	5.85E-04
Ś	Human-Specific	8565	96.12%	36.90%	42.37	< 2E-272	96.55%	41.12%	40.00	< 2E-272	94.31%	27.48%	43.60	3.24E-186	93.82%	25.82%	43.13	8.34E-72	94.62%	28.48%	43.90	5.22E-115
nan	Two-Cell Mixed	6287	91.55%	33.78%	21.24	< 2E-272	92.48%	37.65%	20.37	< 2E-272	88.04%	25.37%	21.59	1.40E-137	87.78%	27.42%	18.89	5.61E-52	88.23%	24.04%	23.55	4.05E-86
	Three-Cell	12687	90.95%	34.89%	18.76	< 2E-272	91.65%	39.36%	16.91	< 2E-272	87.77%	23.85%	22.88	2.31E-230	88.84%	23.74%	25.44	2.33E-92	87.09%	23.91%	21.41	1.20E-138
	MCKG	53642	37.48%	28.19%	1.53	1.42E-212	39.59%	32.61%	1.35	1.42E-212	31.74%	23.62%	1.50	4.34E-29	28.35%	22.21%	1.39	3.51E-07	33.72%	24.44%	1.57	3.04E-23
	Total	209768	51.63%	27.84%	2.77	< 2E-272	55.86%	31.46%	2.76	< 2E-272	38.03%	21.72%	2.21	< 2E-272	33.46%	20.81%	1.91	2.47E-154	48.56%	23.57%	3.06	1.49E-248
All	Total.hg19	84713	44.91%	27.69%	2.13	< 2E-272	48.99%	31.42%	2.10	< 2E-272	33.58%	21.76%	1.82	8.23E-180	27.56%	20.64%	1.46	1.95E-45	46.47%	23.89%	2.77	1.68E-196
	Total.mm9	125055	47.50%	26.10%	2.56	< 2E-272	52.47%	29.28%	2.67	< 2E-272	31.36%	20.11%	1.82	5.40E-109	29.87%	20.17%	1.69	8.48E-74	43.40%	19.53%	3.16	3.75E-47

#GWAS Ontology Term	Category
aggressive behavior	behavior
alcohol dependence	behavior
alcohol drinking	behavior
behavior or behavioral disorder measurement	behavior
coffee consumption	behavior
cups of coffee per day measurement	behavior
illegal drug consumption	behavior behavior
nicotine use non-substance related disinhibited behaviour	behavior
smoking behavior	behavior
smoking behaviour measurement	behavior
smoking cessation	behavior
smoking initiation	behavior
aging	biological_process
energy expenditure	biological_process
energy intake	biological_process
physical activity	biological_process
sneezing	biological_process
albumin:globulin ratio measurement	blood
alpha globulin measurement blood metabolite measurement	blood blood
blood sedimentation	blood
coagulation factor measurement	blood
erythrocyte count	blood
erythrocyte measurement	blood
factor VIII measurement	blood
fetal hemoglobin measurement	blood
fibrinogen measurement	blood
hematocrit	blood
hematological measurement	blood
hemoglobin A2 measurement	blood
hemoglobin E disease	blood
hemoglobin measurement	blood blood
mean corpuscular hemoglobin mean corpuscular hemoglobin concentration	blood
mean corpuscular volume	blood
mean platelet volume	blood
partial thromboplastin time	blood
platelet aggregation	blood
platelet count	blood
protein c measurement	blood
red blood cell distribution width	blood
sickle cell anemia	blood
total blood protein measurement	blood
von Willebrand factor measurement	blood
ankle brachial index	body_measurement
anthropometry	body_measurement
arm span Attached earlobe	body_measurement body_measurement
axial length measurement	body_measurement
birth weight	body_measurement
body composition measurement	body_measurement
body fat distribution	body_measurement
body height	body_measurement
body mass index	body_measurement
body weight	body_measurement
dense area measurement	body_measurement
foot	body_measurement
head circumference	body_measurement
height growth measurement height-adjusted body mass index	body_measurement
height-adjusted body mass index hip bone size	body_measurement body_measurement
hip circumference	body_measurement
hip geometry	body_measurement
infant body height	body_measurement
infant head circumference	body_measurement
intracranial volume	body_measurement
lean body mass	body_measurement
mammographic density measurement	body_measurement
mammographic density percentage	body_measurement
metabolic rate measurement	body_measurement
non-dense area measurement	body_measurement
spine bone size	body_measurement
cuboutopoous adipasa tissua pagaguramant	body_measurement
subcutaneous adipose tissue measurement visceral adipose tissue measurement	body_measurement

#GWAS Ontology Term	Category
waist circumference	body_measurement
waist-hip ratio	body measurement
bone density	bone
braces	bone
osteitis deformans	bone
scoliosis	bone
alpha peak frequency measurement	brain
alpha wave measurement	brain
beta wave measurement	brain
brain measurement	brain
brain serotonin transporter measurement	brain
cognition	brain
cortical thickness	brain
delta wave measurement	brain
electroencephalogram measurement	brain
frontal theta oscillation measurement	brain
Heschl's gyrus morphology measurement	brain
hippocampal volume	brain
information processing speed	brain
intelligence lentiform nucleus volume	brain brain
mathematical ability	brain
memory performance	brain
memory, short-term	brain
mental process	brain
neurofibrilliary tangles measurement	brain
paragraph delayed recall measurement	brain
reasoning	brain
self reported educational attainment	brain
superior frontal gyrus grey matter volume measu	
theta wave measurement	brain
volumetric brain mri	brain
white matter integrity	brain
white matter microstructure measurement	brain
word list delayed recall measurement	brain
word reading	brain
Alzheimer's disease neuropathologic change	brain_disease
Alzheimers disease	brain_disease
anorexia nervosa	brain_disease
anxiety	brain_disease
anxiety disorder	brain_disease
asperger syndrome	brain_disease
attention deficit hyperactivity disorder	brain_disease
autism	brain_disease
autism spectrum disorder	brain_disease
autism spectrum disorder symptom	brain_disease
bipolar disorder	brain_disease
bulimia nervosa	brain_disease
conduct disorder	brain_disease
dementia	brain_disease
drug dependence	brain_disease
dyslexia	brain_disease
eating disorder epilepsy	brain_disease brain_disease
hippocampal atrophy	brain_disease
HVA measurement	brain_disease
insomnia	brain_disease
language impairment	brain_disease
Lewy body dementia	brain_disease
Lewy body dementia measurement	brain_disease
mental or behavioural disorder	brain_disease
MHPG measurement	brain_disease
migraine disorder	brain_disease
migraine with aura	brain disease
migraine without aura	brain disease
mood disorder	brain_disease
narcolepsy	_ brain_disease
neuritic plaque measurement	_ brain_disease
neuropsychological test	_ brain_disease
nicotine dependence	brain_disease
p-tau measurement	brain_disease
panic disorder	brain_disease
parkinson's disease	brain_disease
plasma beta-amyloid 1-40 measurement	brain_disease
plasma beta-amyloid 1-42 measurement	brain_disease
post-traumatic stress disorder	brain_disease

#GWAS Ontology Term	Category
progressive supranuclear palsy	brain_disease
psychosis	brain disease
psychotic symptoms	 brain_disease
schizoaffective disorder	brain_disease
schizophrenia	brain_disease
social communication impairment suicidal ideation	brain_disease brain disease
unipolar depression	brain disease
acute lymphoblastic leukemia	cancer
B-cell acute lymphoblastic leukemia	cancer
bladder carcinoma	cancer
breast carcinoma	cancer
cancer biomarker measurement central nervous system cancer	cancer cancer
cervical carcinoma	cancer
chronic lymphocytic leukemia	cancer
colorectal cancer	cancer
diffuse large b-cell lymphoma	cancer
Esophageal adenocarcinoma	cancer
esophageal carcinoma esophageal squamous cell carcinoma	cancer cancer
gastric carcinoma	cancer
hepatocellular carcinoma	cancer
hodgkins lymphoma	cancer
igfbp-3 measurement	cancer
lung adenocarcinoma	cancer
lung carcinoma lymphoma	cancer cancer
malignant epithelial tumor of ovary	cancer
marginal zone B-cell lymphoma	cancer
melanoma	cancer
multiple myeloma	cancer
neoplasm of mature b-cells nephroblastoma	cancer
neuroblastoma	cancer cancer
nevus	cancer
nodular sclerosis Hodgkin lymphoma	cancer
non-small cell lung carcinoma	cancer
osteosarcoma	cancer
ovarian carcinoma pancreatic carcinoma	cancer cancer
prostate carcinoma	cancer
prostate specific antigen measurement	cancer
renal cell carcinoma	cancer
serum carcinoembryonic antigen measurement	cancer
squamous cell carcinoma	cancer
testicular carcinoma triple-negative breast cancer	cancer cancer
abdominal aortic artery calcification	cardiovascular
aortic root size	cardiovascular
asymmetrical dimethylarginine measurement	cardiovascular
atrial fibrillation	cardiovascular
blood pressure	cardiovascular cardiovascular
brain aneurysm Brugada syndrome	cardiovascular
cardiac hypertrophy	cardiovascular
cardiac troponin T measurement	cardiovascular
cardiovascular disease	cardiovascular
cardiovascular measurement	cardiovascular
carotid artery disease	cardiovascular cardiovascular
cis/trans-18:2 fatty acid measurement common carotid intimal medial thickness	cardiovascular
conotruncal heart defect	cardiovascular
coronary artery calcification	cardiovascular
coronary heart disease	cardiovascular
creatine kinase measurement	cardiovascular
diastolic blood pressure	cardiovascular cardiovascular
dihydroxy docosatrienoic acid measurement ejection fraction measurement	cardiovascular cardiovascular
electrocardiography	cardiovascular
exercise test	cardiovascular
heart failure	cardiovascular
heart function measurement	cardiovascular
heart rate	cardiovascular
Hydroxy-leucine measurement hypertension	cardiovascular cardiovascular
Appendension	

#GWAS Ontology Term	Category
icam-1 measurement	cardiovascular
internal carotid intimal medial thickness	cardiovascular
large artery stroke	cardiovascular
lipoprotein-associated phospholipase a(2) measur	cardiovascular
myeloperoxidase measurement	cardiovascular
myocardial infarction	cardiovascular
nt-probnp measurement	cardiovascular
P wave duration pr interval	cardiovascular cardiovascular
PR segment	cardiovascular
pulmonary artery enlargement	cardiovascular
pulmonary function measurement	cardiovascular
pyroglutamine measurement	cardiovascular
QRS complex	cardiovascular
QRS duration	cardiovascular
qt interval	cardiovascular cardiovascular
resting heart rate rr interval	cardiovascular
serum homoarginine measurement	cardiovascular
serum ST2 measurement	cardiovascular
soluble p-selectin measurement	cardiovascular
stroke	cardiovascular
sudden cardiac arrest	cardiovascular
systolic blood pressure	cardiovascular
tissue plasminogen activator measurement total trans-18:1 fatty acid measurement	cardiovas cular cardiovas cular
trans fatty acid measurement	cardiovascular
trans-16:1n-7 fatty acid measurement	cardiovascular
trans/cis-18:2 fatty acid measurement	cardiovascular
trans/trans-18:2 fatty acid measurement	cardiovascular
triglyceride measurement	cardiovascular
uric acid measurement	cardiovascular
venous thromboembolism	cardiovascular
androgenetic alopecia eye color	common_traits common_traits
hair color	common_traits
hair morphology	common_traits
personality	common_traits
personality trait	common_traits
temperament and character inventory	common_traits
dental caries	dental
molar-incisor hypomineralization	dental dental
odontogenesis periodontitis	dental
pit and fissure surface dental caries	dental
, smooth surface dental caries	dental
tooth agenesis	dental
tooth eruption	dental
neonate	developmental_stage
a1c measurement	diabetes diabetes
acute insulin response measurement disposition index measurement	diabetes
fasting blood glucose measurement	diabetes
fasting blood insulin measurement	diabetes
glucose effectiveness measurement	diabetes
glucose homeostasis measurement	diabetes
HOMA-IR	diabetes
insulin metabolic clearance rate measurement insulin resistance	diabetes diabetes
insulin sensitivity measurement	diabetes
resistin measurement	diabetes
type 1 diabetes nephropathy	diabetes
type ii diabetes mellitus	diabetes
aspirin induced asthma	drug_response
chemotherapy-induced hypertension	drug_response
cumulative dose response to bevacizumab	drug_response
drug-induced agranulocytosis	drug_response
drug-induced liver injury response to anticoagulant	drug_response drug_response
response to anticonvulsant	drug_response
response to antidepressant	drug_response
response to antimicrotubule agent	drug_response
response to antineoplastic agent	drug_response
response to antipsychotic drug	drug_response
response to bevacizumab response to bronchodilator	drug_response drug_response
	a.ag_response

#GWAS Ontology Term	Category
response to candesartan	drug_response
response to carboplatin	drug_response
response to clozapine	drug_response
response to corticosteroid	drug_response
response to cyclophosphamide response to cytosine arabinoside	drug_response drug_response
response to docetaxel	drug_response
response to drug	drug_response
response to efavirenz	drug_response
response to etoposide	drug_response
response to fenofibrate	drug_response
response to gemcitabine response to haloperidol	drug_response drug_response
response to hydrochlorothiazide	drug_response
response to interferon beta	drug_response
response to irinotecan	drug_response
response to methotrexate	drug_response
response to methylphenidate	drug_response
response to paclitaxel	drug_response
response to platinum based chemotherapy	drug_response
response to reverse transcriptase inhibitor response to selective serotonin reuptake inhibitor	drug_response
response to statin	drug_response
response to vitamin	drug response
Abnormality of refraction	eye
age-related cataract	eye
age-related macular degeneration	eye
Astigmatism	eye
contrast sensitivity measurement	eye
corneal topography diabetic retinopathy	eye eye
exfoliation syndrome	eye
eye measurement	eye
hypermetropia	eye
intraocular pressure measurement	eye
Myopia	eye
open-angle glaucoma	eye
optic disc size measurement	eye
pathological myopia retinopathy	eye eye
rhegmatogenous retinal detachment	eve
Barrett's esophagus	gut
celiac disease	gut
Hirschsprung disease	gut
sclerosing cholangitis	gut
cortisol secretion measurement estradiol measurement	hormone_measurement
hormone measurement	hormone_measurement hormone_measurement
insulin measurement	hormone_measurement
leptin measurement	hormone_measurement
leptin receptor measurement	hormone_measurement
parathyroid hormone measurement	hormone_measurement
sex hormone globulin binding measurement	hormone_measurement
thyroid stimulating hormone measurement	hormone_measurement
thyroxine measurement acne	hormone_measurement immune_system
aids	immune_system
allergic sensitization measurement	immune_system
allergy	immune_system
alloimmunization	immune_system
alopecia areata	immune_system
ankylosing spondylitis	immune_system
anti-Heliobacter pylori serum IgG measurement anti-neutrophil antibody associated vasculitis	immune_system
antibody measurement	immune_system immune_system
antiphospholipid antibody measurement	immune_system
atopic eczema	immune_system
atopy	immune_system
autoantibody measurement	immune_system
autoimmune hepatits type 1	immune_system
Behcet's disease ccl2 measurement	immune_system
ccl2 measurement CCL4 measurement	immune_system immune_system
CCL5 measurement	immune_system
chronic childhood arthritis	immune_system
chronic hepatitis B infection	immune_system

#GWAS Ontology Term	Category
chronic hepatitis C infection	immune_system
complement C3 measurement	immune_system
complement C4 measurement crohn's disease	immune_system immune_system
eosinophil count	immune_system
eosinophilic esophagitis	immune_system
Epstein-Barr virus infection	immune_system
graves disease	immune_system
hepatitis B infection	immune_system
HIV viral set point measurement	immune_system
HIV-1 infection	immune_system
iga glomerulonephritis	immune_system
IgF-1 measurement immune system disease	immune_system immune_system
inflammatory bowel disease	immune_system
interleukin 1 receptor antagonist measurement	immune_system
interleukin 12 measurement	immune_system
interleukin 18 measurement	immune_system
interleukin-1 beta measurement	immune_system
interleukin-6 measurement	immune_system
interleukin-6 receptor measurement interleukin-8 measurement	immune_system immune_system
irritable bowel syndrome	immune_system
leukocyte count	immune_system
malaria	immune system
monocyte count	immune_system
monocyte early outgrowth colony forming unit	immune_system
multiple sclerosis	immune_system
neutrophil count	immune_system
osteoarthritis	immune_system
parasitemia measurement	immune_system
psoriasis pyoderma gangrenosum	immune_system immune_system
response to dietary antigen	immune_system
response to vaccine	immune_system
response to virus	immune_system
rheumatoid arthritis	immune_system
seasonal allergic rhinitis	immune_system
serum IgE measurement	immune_system
serum IgG glycosylation measurement	immune_system
serum IgG measurement serum IgM measurement	immune_system immune_system
Sjogren syndrome	immune_system
Staphylococcus aureus infection	immune system
systemic lupus erythematosus	immune_system
systemic scleroderma	immune_system
thyroid peroxidase antibody measurement	immune_system
Trypanosoma cruzi seropositivity	immune_system
tuberculosis	immune_system
type i diabetes mellitus	immune_system
ulcerative colitis virologic response measurement	immune_system immune_system
vitiligo	immune_system
apolipoprotein a 1 measurement	inflammatory_measuremen
c-reactive protein measurement	inflammatory_measurement
cytokine measurement	inflammatory_measurement
interleukin 10 measurement	inflammatory_measuremen
l lactate dehydrogenase measurement	inflammatory_measurement
serum amyloid a protein measurement	inflammatory_measuremen
transforming growth factor beta measurement	inflammatory_measuremen
tumor necrosis factor-alpha measurement ykl40 measurement	inflammatory_measuremen
alpha macroglobulin measurement	inflammatory_measuremen kidney
blood urea nitrogen measurement	kidney
chronic kidney disease	kidney
diabetic nephropathy	kidney
kidney disease	kidney
membranous glomerulonephritis	kidney
nephrotic syndrome	kidney
renal system measurement	kidney
serum creatinine measurement	kidney
alkaline phosphatase measurement aspartate aminotransferase measurement	liver liver
biliary atresia	liver
,	
biliary liver cirrhosis	liver

#GWAS Ontology Term	Category
butyrylcholinesterase measurement	liver
hepatitis C induced liver cirrhosis	liver
liver enzyme measurement non-alcoholic fatty liver disease	liver liver
serum alanine aminotransferase measurement	liver
serum albumin measurement	liver
serum gamma-glutamyl transferase measuremen	liver
airway responsiveness measurement	lung
airway wall thickness measurement	lung
asthma	lung
bronchopulmonary dysplasia CC16 measurement	lung
childhood onset asthma	lung lung
chronic bronchitis	lung
chronic obstructive pulmonary disease	lung
cystic fibrosis	lung
emphysema	lung
fev/fec ratio	lung
forced expiratory volume idiopathic pulmonary fibrosis	lung
interstitial lung disease	lung lung
maximal midexpiratory flow rate	lung
maximal oxygen uptake measurement	lung
surfactant protein D measurement	lung
vital capacity	lung
5-HIAA measurement	nervous_system
age-related hearing impairment	nervous_system
amyotrophic lateral sclerosis circadian rhythm	nervous_system nervous_system
febrile seizures	nervous_system
MMR-related febrile seizures	nervous_system
sensory perception of smell	nervous_system
sensory perception of taste	nervous_system
sporadic amyotrophic lateral sclerosis	nervous_system
cleft lip	other_disease
dupuytren contracture Ieprosy	other_disease other_disease
lumbar disc degeneration	other_disease
mucocutaneous lymph node syndrome	other_disease
orofacial clefting syndrome	
pancreatitis	other_disease
prion disease	other_disease
sarcoidosis	other_disease
stevens-johnson syndrome adhesion molecule measurement	other_disease other_measurement
adiponectin measurement	other_measurement
age at onset	other_measurement
amino acid measurement	other_measurement
antioxidant measurement	other_measurement
antisaccade response measurement	other_measurement
arachidonic acid measurement	other_measurement
asbestos exposure measurement beta-2 microglobulin measurement	other_measurement other_measurement
calcium measurement	other_measurement
cotinine glucuronidation measurement	other_measurement
DNA methylation	other_measurement
docosapentaenoic acid measurement	other_measurement
economic and social preference	other_measurement
electrodermal activity measurement	other_measurement
event free survival time	other_measurement
fatty acid measurement ferritin measurement	other_measurement other measurement
folic acid measurement	other_measurement
fructose-bisphosphate aldolase measurement	other_measurement
functional laterality	_ other_measurement
genetic variation	other_measurement
glycoprotein measurement	other_measurement
high density lipoprotein cholesterol measuremen	_
homocysteine measurement	other_measurement
IGFBP-1 measurement	other_measurement other_measurement
insulin like growth factor measurement	ioniei_measurement
insulin like growth factor measurement iron biomarker measurement	other measurement
insulin like growth factor measurement iron biomarker measurement linoleic acid measurement	other_measurement other_measurement
iron biomarker measurement	
iron biomarker measurement linoleic acid measurement	other_measurement

#GWAS Ontology Term	Category
low density lipoprotein cholesterol measurement	other_measurement
magnesium measurement	other_measurement
matrix metalloproteinase measurement	other_measurement
metabolite measurement	other_measurement
mitochondrial DNA measurement	other_measurement
mortality	other_measurement
myoglobin measurement	other_measurement
N-glycan measurement	other_measurement
nitric oxide exhalation measurement	other_measurement
oligoclonal band measurement	other_measurement
omega-6 polyunsaturated fatty acid measuremen	_
phospholipid measurement phosphorus measurement	other_measurement other measurement
plasminogen activator inhibitor 1 measurement	other measurement
protein measurement	other_measurement
selenium measurement	other_measurement
self rated health	other_measurement
serum copper measurement	other_measurement
serum dimethylarginine measurement	other_measurement
serum iron measurement	other_measurement
serum metabolite measurement	other_measurement
serum selenium measurement	other_measurement
serum zinc measurement	other_measurement
short sleep	other_measurement
skin conductance level	other_measurement
skin conductance response amplitude	other_measurement
skin conductance response frequency	other_measurement
sleep duration	other_measurement
sleep measurement	other_measurement
soluble transferrin receptor measurement	other_measurement
sphingolipid measurement	other_measurement
survival time	other_measurement
telomere length	other_measurement
total cholesterol measurement	other_measurement
transferrin measurement	other_measurement
transferrin saturation measurement	other_measurement
urate measurement	other_measurement
urinary metabolite measurement	other_measurement
urinary uromodulin measurement	other_measurement
very long-chain saturated fatty acid measurement	—
vitamin B12 measurement	other_measurement
vitamin D measurement	other_measurement
vitamin measurement	other_measurement
metabolic syndrome	other_metabolic_disord
obesity	other_metabolic_disord
overweight body mass index status age at menarche	other_metabolic_disorde
-	reproductive reproductive
age at menopause azoospermia	reproductive
endometriosis	reproductive
erectile dysfunction	reproductive
follicle stimulating hormone measurement	reproductive
gestational age	reproductive
hypospadias	reproductive
male infertility	reproductive
polycystic ovary syndrome	reproductive
preeclampsia	reproductive
puberty	reproductive
puberty onset measurement	reproductive
sexual dysfunction	reproductive
testosterone measurement	reproductive
uterine fibroid	reproductive
auntan	skin
suntan	L
toxic epidermal necrolysis	skin
	stimulus_response
toxic epidermal necrolysis	

ObservedObservedPreventor<	Table S9								
Information yound lonse 44 15 0.000000 0.00000 0.000000			•	•					•
immute system disase16150.001610.0079400.580.4560.158 hold blockanalysis extension662.00.012170.027722.282.00163.885 hold immute systemanalysis extension662.00.012170.027722.282.00163.885 hold immute systemand reference system662.0012170.012782.184.0662.057 hold immute systemand reference system662.001210.002482.184.0662.057 hold immute systemand reference system660.000780.001810.00482.067 hold immute systemand reference system660.000780.001860.001860.001862.057 hold immute systemand reference system660.000580.0019864.081.187 hold 3.177 hold andand reference shrints61610.000580.0019864.081.187 hold 3.1677and reference shrints61610.000580.0019864.081.187 hold 3.1277 hold 3.1677and reference shrints61610.000580.0019861.081.187 hold 3.1277 hold 3.1677and reference shrints61610.000580.0019861.081.187 hold 3.1277 hold 3.1677and reference shrints61610.000580.0019861.081.184 hold 3.1278 hold 3								. ,	
enymous 13 0.02.520 0.01144 1.43 3.75.50 1.15.50 job of job of									
minipacticols 65 72.7 72.22 72.82.6 <th72.82.6< th=""> 72.82.6 <th72.8< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th72.8<></th72.82.6<>									
systemic space space systemic space space systemic space s									
systemic size decama1110.002210.0028330.0061.01040.002660.002660.002660.002660.002660.002660.0011010.002660.000660.0011010.002660.000660.0011010.002660.000660.0011010.002660.00108 <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>— — — — — — — — — — — — — — — — — — — —</td>	-								— — — — — — — — — — — — — — — — — — — —
sind-selection just service 5 0 0.00216 0.022481 1 4.864-00 2.652-00 more_system ubcrative colits 38 11 0.07762 0.01786 2.44 4.54-00 2.652-00 more_system ubcrative colits 38 12 0.00782 0.01786 2.44 4.54-00 more_system esophage squantos cell carcinona 38 12 0.00058 0.01987 1.82 3.31-05 1.74-00 ancer esophage squantos cell carcinona 15 1.8 0.00051 0.01981 0.01817 0.01801 0.01817 0.01801 0.01817 0.0181 0.01817 0.0181	crohn's disease	54	25	0.012287	0.026799	2.18	2.03E-07	1.64E-05	immune_system
self accords elucisonal stamment 24 50 000078 0000780 </td <td>systemic scleroderma</td> <td></td> <td>4</td> <td>0.002213</td> <td>0.008933</td> <td>4.04</td> <td>1.09E-06</td> <td>7.59E-05</td> <td>immune_system</td>	systemic scleroderma		4	0.002213	0.008933	4.04	1.09E-06	7.59E-05	immune_system
ukernise colins36110.0076280.01780531.464.464.000.001080.0013970.454.000.001080.0003970.454.000.0003970.454.000.0003970.454.000.0003970.454.000.0003970.454.000.0003970.454.000.0003970.17700.1770.00									—
mod dorder esphagai syumous ell archoma 64 0.00008 0.00									
ecohyanale signamous cell arginomais a0.00000000.00000000.0000000.0000000.0000000.0000000.0000000.0000000.0000000.00000000.00000000.0000000.00000000.000000<									
neuronal elegentinis536363608.816 of1.426 03 hermane_systemparimon's disease29130.006430.014392.276.376.02.356.40 hermane_systemblocd metabolite measurement44100.004830.014391.2483.046.30 hermane_systemblocd metabolite measurement44100.001180.001181.0183.256.40 hloodintracranial volume67440.020330.012311.311.1416.03.866.00 hermane_systemshizophenia67410.0053570.012372.312.1416.03.866.00 hermane_systempartiesis130.005370.012412.312.746.06.336.00 hermane_systempartiesis130.005410.005410.03445.243.816.08.660 hermane_systempartiesis130.0026410.03870.0231.476.03.866.0A.866.0partiesis140.0026310.002630.2214.746.00.010 immune_systempartiesis130.0026410.03872.221.116.00.0011partiesis140.002380.002632.221.116.00.023partiesis140.002380.002631.291.116.00.023partiesis140.002380.002631.290.0231.002partiesis140.002390.00281.290.0230.002partiesis150.002760.00281.29 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td></t<>									-
second allerge rhints 15 44 0.00215 0.007444 0.484 0.48456 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.68676 0.2385 0.68767 0.2385 0.6876 0.238 0.0357 0.23 0.0357 0.237 0.238 0.0357 0.238 0.0357 0.238 0.0357 0.237 0.035 0.0357 0.237 0.035 0.0357 0.237 0.238 0.035 0.035 0.035 0.035									
parkinory disase 29 13 0.006437 0.01492 2.27 6.376.0 2.356.6.0 bind, measurement biod metabolite messurement 47 0.00243 0.01235 1.14 8.300.0 2.286.6.0 bind, measurement shizaphenia 67 0.0116 0.00245 0.03235 1.14 8.300.0 2.286.4.0 bind, measurement shizaphenia 67 1.0 0.00453 0.0114 0.233 2.145.0 3.86.6.0 bind, measurement particles 1.0 0.00453 0.00144 0.23 2.746.0 8.87.6.0 bind, measurement particles 2.3 0.00237 0.00248 0.00144 0.011 imme, system particles 2.3 0.00237 0.00248 0.021 0.011 imme, system particles 2.4 0.00038 0.00238 0.0228 0.023 0.014 inter, system uate messurement 1.8 0.00038 0.0238 0.22 1.286.0 0.024 inter, system uate messurement 1.8 0.00024 0.0038 6.22 1	seasonal allergic rhinitis								
bladd metabolite masurement: 147 25 0.021240 0.021342 0.021342 0.021352 0.02154 0.020154 0.021352 0.00155 0.00156 0.025540 0.001144 0.02147 0.03325 0.00147 0.03325 0.00147 0.0		29	13	0.006347	0.014392	2.27	6.37E-05	2.06E-03	brain_disease
intracial volume 4 0 0.00189 0.00283 1.05 1.054 2.252.50 good, measurement pitele rount 25 11 0.00283 0.01240 2.3 1.344.40 3.846.01 glood colorectal cancer 25 11 0.00284 0.01240 2.345.40 8.346.01 glood progressive supraructer palsy 7 1 0.00084 0.00144 0.52 3.247.40 8.346.01 glood potensis 2.376.40 0.00181 0.00084 0.26 7.297.60 0.0111 limurue, system allergy 12 4 0.00031 0.00083 0.22 1.276.80 0.0012 limurue, system allergy 12 0.00084 0.00083 0.22 1.276.80 0.0012 limurue, system allergy 12 0.00084 0.00083 0.22 1.276.80 0.0012 limurue, system allergy 12 0.00084 0.00083 0.22 1.376.80 0.0012 limurue, system allergy 0.0016 0.00028 0.00185 0.68	metabolite measurement	24	10	0.004833	0.011911	2.46	7.74E-05	2.35E-03	other_measurement
scheapernia 66 41 0.03320 0.03327 1.38 41.44 3.348-03 100111 coloracti cancer 23 10 0.00540 0.01341 2.33 2.74-04 5.346-03 5.346-0	blood metabolite measurement	47						2.37E-03	blood
plateic cont. 25 11 0.05337 0.012407 2.22 2.4E-04 3.48E-03 biolar progressive supranuclear palsy 7 1 0.000434 0.001444 5.42 3.4E-04 8.49E-03 biolar portaits 0.002387 0.002387 0.002387 0.001 minume_system plateit agregation 12 0.000387 0.002387 0.001 0.0011 minume_system altery 12 0.000387 0.00387 0.22 0.0013 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014 0.0014									
colorectal cancer 23 10 0.00444 0.214 2.21 2.214-04 6.334-03 concer porgressive sumulator palyy 14 0.000474 0.00144 0.24 3.844-00 0.0011 block pordressive sumulator paly 12 0.00032 0.00935 3.24 5.246-00 0.0011 block particlet aggregation 12 4.0 0.00035 0.00357 4.25 7.246-00 0.0011 http:::::::::::::::::::::::::::::::::::	-								-
progressive sportation710.000410.000440.5423.84.008.49.00Name_systemplatel agregation1240.001660.005953.305.25.00.0011Nome_systemplatel agregation1240.002380.0039703.205.25.21.12.630.0011Nome_systemallery1240.002380.0039703.201.58.400.0226Antoresurementcardiac tropont I measurement1880.0039703.211.58.400.0226Antoresurementtalial body protein measurement1510.0002810.0039703.215.26.00.0028Body Corecardiac tropont I measurement410.0002910.014881.21.16.030.0046cheradhesion molecule measurement410.0002910.018956.823.10.6030.0046cherensorement410.0002910.018956.823.10.6030.0046cherensorement510.0002910.018956.823.10.6030.0046cherensorement610.0002910.0018956.823.10.6030.0046cherensorement610.0002910.0018956.823.10.6030.0046cherensorement610.0002910.0018956.820.0014chercherensorement610.0002910.0018956.820.									
panalsi patielt agregation 14 5 0.02387 0.009395 2.21 4.74-c4 0.001 Immune system functional laterality 8 2 0.003930 4.26 7.26-c4 0.011 Imbure system allery 12 24 0.003930 2.29 1.12-c5 0.012 Imbure system urate measurement 18 8 0.003970 3.29 1.53-c5 0.025 (ardiovscular cardia troponin T measurement 5 1 0.003970 0.03985 6.22 1.51-c5 0.025 (ardiovscular cardia troponin T measurement 5 1 0.000397 0.03185 6.82 3.16-c6 0.025 (ardiovscular arbiston molecumeasurement 4 1 0.000215 6.82 3.16-c6 0.046 (arbit									
pitete agregation 12 4 0.00165 0.003955 3.20 5.26E-04 0.011 blood allergy 12 4 0.002305 0.02375 2.29 1.02E-03 0.0231 immune_system allergy 12 4 0.002305 0.295 1.32E-03 0.023 endivascular allergy 13 0.00141 0.002370 3.75 1.33E-03 0.023 endivascular contary hard fieldsase 30 11 0.000231 0.01185 6.82 3.10E-03 0.0046 ohder measurement contary hard fieldsase 4 1 0.000231 0.00185 6.82 3.10E-03 0.0046 fordivascular magnesium measurement 4 1 0.000231 0.00185 6.82 3.10E-03 0.0046 fordivascular magnesium measurement 4 1 0.000231 0.00241 4.73 4.58E-03 0.0064 fordivascular magnesium measurement 2 0.0000351 0.00297 6.3									-
functional laterality 18 2 0.000370 4.26 7.25E-04 0.014 other_measurement allery 12 4 0.00390 0.00593 2.23 1.12E-03 0.023 other_messurement cardia troponin T measurement 8 1 0.001048 0.003970 3.79 1.35E-03 0.023 cardioxscular cardia troponin T measurement 8 1 0.000287 0.01885 6.82 3.10E-03 0.0046 cardioxscular arbision molecomessurement 4 1 0.00029 0.00185 6.82 3.10E-03 0.0046 cardioxscular arbision molecomessurement 5 1 0.00029 0.00185 6.82 3.10E-03 0.0046 cardioxscular magnetsium measurement 5 1 0.00029 0.00241 4.38E-03 0.0064 cher_measurement response to infortean 7 8 0.00031 0.0024 5.38E-03 0.0073 blood seruada sortome 11 4 0.00024 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>— ·</td>									— ·
urate 18 8 0.008931 2.2.9 1.2.9.6.3 0.0.2.3 other_measurement cardiac topolin Tmeasurement 5 1 0.00843 0.6.9 1.5.8.63 0.0.2.6 blood caronary hart disease 30 17 0.00827 0.14888 1.7.9 0.0385 cardia topolic 0.0385 cardia topolic 0.0385 cardia topolic 0.0385 cardia topolic cardia topolic 0.0385 cardia topolic 0.0385 cardia topolic cardi				0.000932	0.003970	4.26	7.29E-04		
crdiat troppnin T mesurement 58 2 0.003970 3.78 1.53.63 0.026 (ardiovasular) total body protein mesurement 30 11 0.008327 0.01488 1.79 2.17E-03 0.036 (ardiovasular) adhesion molecule mesurement 44 1 0.001985 6.82 3.10E-03 0.046 (other, measurement) magnesium mesurement 44 1 0.002981 6.42 3.10E-03 0.046 (other, measurement) mean corpuscular volume 55 1 0.00241 4.73 4.58E-03 0.046 (other, measurement) mean corpuscular volume 17 8 0.00241 4.73 4.58E-03 0.0047 (other) (other) Brugads syndrome 13 0.00271 0.00148 8.52E 5.55E-03 0.037 (ardiovasular) serum homoziginine measurement 12 0.00015 0.00278 3.65 6.80E-03 0.001 (munus, system) body height 103 172 0.8055 6.80E-03 0.001 (munus, system) ortecorthink 13 0.00223 0.00545	allergy	12	4	0.002038	0.005955	2.92	1.12E-03	0.021	immune_system
total bod protein measurement 5 1 0.002481 6.09 1.58.03 0.026 blood cornary heart disease 30 17 0.00231 0.01985 6.82 3.10-63 0.0046 other_measurement news 44 1 0.00291 0.001985 6.82 3.10-63 0.0046 other_measurement news 44 1 0.00291 0.001985 6.82 3.10-63 0.0046 other_measurement response binitotean 5 11 0.00024 0.00241 4.73 4.58-03 0.006 other_measurement response binitotean 53 0.00213 0.00043 0.00243 5.38-03 0.0073 blood strunt homoarginine measurement 13 4 0.00213 0.000453 0.227 5.58-63 0.0073 blood strunt homoarginine measurement 12 0.00215 0.00278 3.65 6.80-63 0.0011 behavior cotacathritis 6 12 0.00235 0.00278 3.65 6.80-63 0.0011 behavior strunt homoarginine measurem	urate measurement			0.003901	0.008933				_
cornary hand disease 30 17 0.00832 0.01888 1.79 2.17E-03 0.0036 cardiovascular adhesion molecule measurement 4 1 0.000291 0.001985 6.82 3.10E-03 0.046 cardiovascular soluble p-selectin measurement 4 1 0.000291 0.001985 6.82 3.10E-03 0.046 cardiovascular response to irinotecan 55 1 0.00024 0.02483 7.43 4.58E-03 0.064 ober, measurement Brugada syndrome 3 0 0.000175 0.001489 8.52 5.59E-03 0.073 blood serum homorghine measurement 2 0 0.000175 0.001489 8.52 5.59E-03 0.0019 behavior octeanthritis 6 2 0.00035 0.00278 3.65 6.60E-03 0.0681 memues, stem body height 203 172 0.08520 0.1074 1.18 8.20E-03 0.0095 body_measurement chrotin tymphocytic leuk	-								
adhesion molecule measurement 44 11 0.000291 0.001985 6.6.22 3.106-03 0.0.046 cancer newus 0.001984 0.001985 6.6.2 3.106-03 0.0.046 cancer soluble petetcin measurement 4 0.00024 0.00248 4.7.3 4.58E-03 0.0.664 drug-resonse response to intotecan 5 1 0.00024 0.00438 4.52 5.58E-03 0.0073 blood Brugada syndrome 37 8 0.00175 0.00148 6.52 0.0073 andiovascular serum homoarginine measurement 2 0.00015 0.00278 3.65 6.60E-03 0.0079 andiovascular serum homoarginine measurement 6 2 0.00015 0.00278 3.65 6.60E-03 0.0081 hehaviar aggressive behavicr 6 2 0.00125 0.00278 3.65 6.0021 0.008 bdy-measurement body height 203 0.0124 0.00235 0.0104 1.88									
news 4 1 0.000291 0.001985 6.82 3.10.6-03 0.046 cancer soluble p-slectin measurement 5 1 0.000291 0.001985 6.82 3.10.6-03 0.064 drug response response to infrotecan 5 1 0.000241 4.73 4.586-03 0.064 drug response mean corpuscular volume 17 8 0.000135 0.00437 2.048 5.986-03 0.073 londd serum homarginine measurement 2 0 0.000155 0.00275 3.65 6.806-03 0.081 behavior octeanthritis 6 2 0.000155 0.00275 3.65 6.806-03 0.081 behavior octeanthritis 6 2 0.000155 0.0275 3.65 6.806-03 0.081 behavior octeanthritis 6 0.02239 0.0255 2.34 8.866-03 0.0103 behavior otteanthritis 6 1 0.000233 0.01045 3.93 <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	-								
solubic p-selectin measurement 4 1 0.000241 0.001985 6.622 3.10-03 0.006 outpactance response to intotecan 5 1 0.000244 0.00434 4.73 4.58E-03 0.066 dirug_response Brugada syndrome 17 8 0.00135 0.00438 8.52 5.59E-03 0.073 londors serun homoarginine measurement 2 0 0.000155 0.000375 3.65 6.80E-03 0.081 henvior osteoarthritis 6 2 0.000155 0.002775 3.65 6.80E-03 0.081 henvine_system obdy height 03 122 0.000155 0.00278 3.65 6.80E-03 0.081 henvine_system obdy height 103 12 0.000235 0.0024 1.18 8.20E-03 0.0103 cancer restricturar carioma 8 3 0.000236 0.00185 4.37 9.90E-03 0.113 cancer restricturarimaeasurement 4 1 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>									
magnesurementS10.000240.0024814.734.886-030.064ther_measurementresponse to irindecan50.005240.0024814.0024812.445.886-030.0073bloodBrugada syndrome30.0001730.0014932.045.886-030.073bloodBrugada syndrome30.0002750.0014898.525.596-030.073bloodserum homoarginine measurement20.0000550.000552.476.376-030.079immune_systemaggressive behavior60.0000150.0002783.656.806-030.081bnolsotecarthritis620.0002550.1071.188.206-030.008bnolsbody height1150.002390.00552.348.866-030.010cancerprotein c masurement410.0002450.00552.348.866-030.010bloodtexticular carcinoma860.0039702.731.056-020.113cancerprotein c masurement410.000450.01853.792.266-020.121bloodtexticular carcinoma410.000540.01853.792.266-020.125cardiovascularungelopexidas emasurement410.000540.001853.413.156-020.223other_measurementungelopexidas emasurement410.000540.001853.413.156-020.223									
response to ininotecan \$ 1 0.00224 0.02431 4.73 4.88-03 0.064 drug_response mean corpuscular volume 17 8 0.004134 0.00437 2.04 5.384-03 0.073 blood stugad syndrome 3 0 0.000175 0.001489 8.52 5.595-00 0.073 cardiovascular serum homoarginine measurement 2 0 0.000155 0.00293 1.705 6.376-03 0.007 immune_system osteoarthritis 6 2 0.000155 0.002978 3.65 6.806-03 0.00181 behavior osteoarthritis 6 2 0.000155 0.002978 3.65 6.806-03 0.0081 behavior otto hight 2.03 1.03 0.000155 0.00379 2.31 1.056-03 0.0108 bedy height 0.010 cancer testicular carcinoma 8 3 0.001455 0.003370 2.73 1.056-02 0.121 biood testicular carcinoma									
Brugada syndrome I 0 0.000175 0.001375 0.558-03 0.073 cardiovascular vitiligo 11 4 0.00213 0.005459 2.47 6.19E-03 0.079 immune_system aggressive behavior 6 2 0.000015 0.00278 3.65 6.80E-03 0.0011 behavior osteoarthritis 6 2 0.000155 0.00278 3.65 6.80E-03 0.0011 behavior osteoarthritis 0.00 0.000232 0.000445 4.88E-03 0.0010 cancer protein creasurement 4 1 0.000456 0.00379 1.72 0.01456 0.00379 1.05E-02 0.0113 cancer mean platelet volume 13 6 0.00033 0.01459 6.39 1.22E-02 0.113 cancer regresories ensurement 4 1 0.00023 0.01459 6.39 1.22E-02 0.129 behavior vitami measurement 4 1 0.00024 0.01985 3.79 2.26E-02 0.219 behavior vitami measurement	-						4.58E-03		_
vitiligo 11 4 0.002213 0.00993 2.47 6.19E-03 0.079 Immune_system serum homoarginie measurement 2 0 0.000058 0.000978 3.65 6.80E-03 0.0011 bedy height 0.0011 0.000157 0.002778 3.65 6.80E-03 0.0011 himmune_system body height 203 172 0.085250 0.005459 2.34 8.86E-03 0.000 cancer protein c measurement 4 1 0.00048 0.001459 2.34 8.86E-03 0.010 cancer mean platelet volume 13 6 0.00346 0.001459 2.34 8.86E-03 0.010 cancer mesoperotidase measurement 4 1 0.000452 2.09 1.15E-02 0.121 blood cups of coffee per day measurement 4 1 0.000545 3.79 2.26E-02 0.219 behavior vitami measurement 4 1 0.000165 3.46 1.54E-02 0.0128 bav	mean corpuscular volume	17	8	0.004134	0.008437	2.04	5.38E-03	0.073	blood
serun homoarginine measurement 2 0 0.000058 0.000993 17.05 6.37E-03 0.079 cardiovascular aggressive behavior 6 2 0.000815 0.002978 3.56 6.80E-03 0.081 imune_system body height 203 172 0.085250 0.100744 1.18 8.20E-03 0.0095 body_measurement chronic lymphocytic leukemia 11 5 0.002329 0.005459 2.44 8.86E-03 0.1009 ioade protein creasurement 44 1 0.000465 0.003970 2.73 1.05E-02 0.113 cancer mean platelet volume 13 6 0.003085 0.00395 3.79 2.26E-02 0.126 cardiovascular cups of coffee per dy measurement 4 1 0.000524 0.001985 3.79 2.26E-02 0.215 chremasurement vitamin measurement 2 0 0.000146 0.000393 8.52 2.36E-02 0.223 complemet C4 measurement u	Brugada syndrome	3	0	0.000175	0.001489	8.52	5.59E-03	0.073	cardiovascular
aggressive behavior620.0008150.0029783.656.680E-030.081Immune_systemosteoarthritis2031720.0052520.1007441.188.20E-030.005body_measurementchronic lymphocytic leukemia11250.002390.005452.348.86E-030.100cancerprotein c measurement410.0004080.0019854.879.90E-030.1019bloodtesticular carcinoma830.0014560.0033702.731.05E-020.113cancermean platelet volume1360.003330.0014896.391.22E-020.126eyemyeloperoxidase measurement410.000240.0019853.792.26E-020.219behaviorups of offee per day measurement410.0005240.0019853.792.26E-020.219behaviorsabestos exposure measurement410.0005240.0019853.413.15E-020.231behaviorcomplement C3 measurement410.0005240.0019853.413.15E-020.231behaviorcomplement C4 measurement410.0005240.0019853.413.15E-020.238immune_systeminfant body height5220.001670.0014894.263.46E-020.200body_measurementinfant body height5310.0005240.0014894.263.46E-020.200 </td <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	-								
osteoarthritis620.008150.0029783.656.680E-030.081Immune_systembody height2031720.0852500.1007441.188.20E-030.005body_measurementchronic lymphocytic leukemia1150.023290.0054552.348.86E-030.100cancerprotein c measurement410.004080.0019854.879.90E-030.109bloodmean platelet volume1360.003660.0064522.091.15E-020.121bloodrhegmatogenous retinal detachment300.0002330.0019854.261.54E-020.126eyewyeloperoxidase measurement410.0002540.0019853.792.26E-020.219behaviorvitamin measurement410.0005240.0019853.792.26E-020.225other_measurementasbetos exposure measurement200.001160.000938.522.36E-020.225other_measurementgersonality trait1050.002160.0019853.413.15E-020.283immune_systeminfant body height520.000390.0014894.263.46E-020.290immune_systeminfant body height510.005240.0019853.413.15E-020.283immune_systeminfant body height5810.005320.0014894.263.46E-020.290immune_system<	-								
body height 203 172 0.085250 0.100744 1.18 8.20E-03 0.095 body_measurement chronic lymphocytic leukemia 11 5 0.002329 0.005459 2.34 8.86E-03 0.100 cancer protein c measurement 4 1 0.000408 0.001985 4.87 9.90E-03 0.109 blood testicular carcinoma 8 3 0.001456 0.00377 2.7.3 1.05E-02 0.121 blood rhegmatogenous retinal detachment 3 0 0.000233 0.001489 6.39 1.22E-02 0.121 blood cups of coffee per day measurement 4 1 0.000524 0.001985 3.79 2.26E-02 0.219 behavior vitamin measurement 4 1 0.000582 0.00186 3.79 2.26E-02 0.223 inmune_system personality trait 100 5 0.002387 0.001985 3.41 3.15E-02 0.283 immune_system hepatitis Binfection <									
chronic lymphocytic leukemia 11 5 0.002329 0.005459 2.34 8.86E-03 0.100 cancer protein c measurement 4 1 0.000408 0.001985 4.87 9.90E-03 0.109 blood testicular carcinoma 8 3 0.001456 0.003970 2.73 1.05E-02 0.113 cancer mean platelet volume 13 6 0.000233 0.001489 6.39 1.22E-02 0.126 eye myeloperoxidase measurement 4 1 0.000524 0.001985 3.79 2.26E-02 0.219 behavior vitamin measurement 4 0.000524 0.001985 3.79 2.26E-02 0.219 behavior complement C3 measurement 2 0 0.000161 0.000582 0.001985 3.41 3.15E-02 0.235 ontom_traits complement C4 measurement 4 0.000582 0.001885 3.41 3.15E-02 0.238 immune_system infant body height 5 2 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
protein c measurement410.0004080.0019854.879.90E-030.109bloodtesticular carcinoma830.0014560.0039702.731.05E-020.113cancermean platelet volume1360.0030380.0064522.091.15E-020.121bloodrhegmatogenous retinal detachment1300.0002330.0014896.391.22E-020.126eyemyeloperoxidase measurement410.0005240.0019853.792.26E-020.219behaviorvitamin measurement410.0005240.0019853.792.26E-020.225other_measurementasbestos exposure measurement2000.000160.009938.522.36E-020.237common_traitscomplement C3 measurement410.0005240.001853.413.15E-020.283immune_systemcomplement C4 measurement410.0005420.001853.413.15E-020.283immune_systeminfant body height520.003490.0014894.263.46E-020.290loddy-measurementinfant body height17100.0051240.008331.613.54E-020.290loddy-ystemmean carpuscular hemoglobin17100.0052420.008331.613.54E-020.290loddy-ystemmutiple myeloma1380.0027520.0046531.443.79E-020.307anc			_						· —
testicular carcinoma830.0014560.0039702.731.05E-020.113cancermean platelet volume1360.0032330.0064522.091.15E-020.121bloodrhegmatogenous retinal detahment300.0002330.0014896.391.22E-020.126eyemyeloperoxidase measurement410.0005240.0019853.792.26E-020.219behaviorcups of coffee per day measurement410.0005240.0019853.792.26E-020.219other_measurementasbestos exposure measurement410.0005240.0019853.792.26E-020.023other_measurementasbestos exposure measurement410.0005240.0019853.413.15E-020.023other_measurementcomplement C3 measurement410.0005820.001853.413.15E-020.283immune_systemhepatitis B infection310.0003490.0014894.263.46E-020.290immune_systeminfant body height520.0008730.0014894.263.46E-020.290iddney_measurementkidney disease18110.005240.0084371.653.44E-020.290iddney_measurementkidney disease18110.005320.004831.613.54E-020.290iddney_measurementinfant body height520.0025420.0084371.65 <td< td=""><td></td><td></td><td>_</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>			_						
rhegmatogenous retinal detachment 3 0 0.000233 0.001489 6.39 1.22E-02 0.126 eye myeloperoxidase measurement 4 1 0.000466 0.001985 3.79 2.26E-02 0.219 behavior vitami measurement 4 1 0.000524 0.001985 3.79 2.26E-02 0.219 other_measurement asbestos exposure measurement 2 0 0.000116 0.00093 8.52 2.36E-02 0.237 common_traits complement C3 measurement 4 1 0.000582 0.0185 3.41 3.15E-02 0.283 immune_system complement C4 measurement 4 1 0.000582 0.0185 3.41 3.15E-02 0.283 immune_system infant body height 5 2 0.000873 0.002481 2.84 3.35E-02 0.0290 immune_system infant body height 5 2 0.008473 1.65 3.44E-02 0.290 blood sporadic amyotrophic lateral sclerosis	testicular carcinoma	8	3	0.001456	0.003970	2.73	1.05E-02		
myeloperoxidase measurement410.0004660.0019854.261.54E-020.156cardiovascularcups of coffee per day measurement410.0005240.0019853.792.26E-020.219behaviorvitami measurement410.0005240.0019853.792.26E-020.219other_measurementasbestos exposure measurement200.0001160.0009938.522.36E-020.225other_measurementpersonality trait1050.0023870.0049652.082.53E-020.228immune_systemcomplement C3 measurement410.0005820.0019853.413.15E-020.283immune_systemcomplement C4 measurement410.0005820.0019853.413.15E-020.283immune_systeminfant body height520.0008730.0024812.843.35E-020.290biodyinfant body height520.0008730.0024812.843.35E-020.290biodysporadic amyotrophic lateral sclerosis18110.005520.0084371.653.44E-020.290biodysporadic disorder1380.0037270.0064521.734.27E-020.307caccerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseaseshort-term memory410.0006410.0019853.104.21E-020.329	mean platelet volume	13	6	0.003086	0.006452	2.09	1.15E-02	0.121	blood
cups of coffee per day measurement410.0005240.0019853.792.26E-020.219behaviorvitamin measurement410.0005240.0019853.792.26E-020.219other_measurementasbestos exposure measurement200.0001160.0009938.522.36E-020.225other_measurementpersonality trait1050.0023870.0049632.082.53E-020.237common_traitscomplement C3 measurement410.0005820.0019853.413.15E-020.283immune_systemcomplement C4 measurement410.0005820.001893.413.15E-020.290immune_systemhepatitis B infection310.0003490.0014894.263.46E-020.290immune_systeminfant body height520.0003490.0014894.263.46E-020.290kidneykidney disease310.0055140.0048471.653.44E-020.290kidneymean corpuscular hemoglobin17100.0051240.0084371.653.44E-020.292herous_systemmultiple myeloma1050.0025620.004631.943.79E-020.307cancerconduct disorder1380.0037270.004521.734.27E-020.329brain_diseaseshort-term memory410.006410.001853.104.21E-020.349immune_		3		0.000233	0.001489	6.39	1.22E-02	0.126	eye
vitamin measurement410.0005240.0019853.792.26E-020.219other_measurementasbestos exposure measurement200.0001160.0009938.522.36E-020.225other_measurementpersonality trait1050.0023870.0049632.082.53E-020.237common_traitscomplement C3 measurement410.0005820.0019853.413.15E-020.283immune_systemcomplement C4 measurement410.0005820.0018953.413.15E-020.283immune_systeminfant body height510.0003490.001894.263.46E-020.290immune_systemkidney disease310.0003490.0014894.263.46E-020.290indexysporadic amyotrophic lateral sclerosis18110.0051240.0083771.653.44E-020.292nervous_systemnarcolepsy180.01750.0024811.643.54E-020.290indexynervous_systemnarcolepsy180.015240.004631.643.54E-020.307nareernarcolepsy150.0024810.0014891.643.42E-020.307nareershort-term memory1410.001750.004831.643.42E-020.302prain_diseaseshort-term memory140.001750.001750.001933.564.92E-020.349inmune_systembiliary									
asbestos exposure measurement200.0001160.0009938.522.36E-020.0225other_measurementpersonality trait1050.0023870.0049632.082.53E-020.237common_traitscomplement C3 measurement410.0005820.0019853.413.15E-020.283immune_systemhepatitis B infection310.0003490.0014894.263.46E-020.209immune_systeminfant body height520.008730.0024812.843.35E-020.290body_measurementkidney disease310.0051240.0084371.653.44E-020.290body_measurementsporadic amyotrophic lateral sclerosis18110.005220.0084371.653.44E-020.292nervous_systemmultiple myeloma1050.0025620.0049631.943.79E-020.307canceratopic eczema1380.0037270.0064521.734.27E-020.329brain_diseaseshort-term memory410.001450.0014853.104.21E-020.329brain_diseasebillary atresia200.0014750.0029783.234.76E-020.349inmune_systembillary atresia200.001750.0009783.234.76E-020.349inmune_systembillary atresia200.001750.0009783.234.76E-020.349inmune_sy									
personality trait1050.0023870.0049632.082.53E-020.237common_traitscomplement C3 measurement410.0005820.0019853.413.15E-020.283immune_systemcomplement C4 measurement410.0005820.0019853.413.15E-020.283immune_systemhepatitis B infection310.0003490.0014894.263.46E-020.290immune_systeminfant body height520.0003730.0024812.843.35E-020.290body_measurementkidney disease310.0051240.0084371.653.44E-020.290kidneymean corpuscular hemoglobin17100.0051240.0084331.613.54E-020.292nervous_systemmultiple myeloma1050.0025620.0049631.943.79E-020.307cancerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseaseatopic eczema730.001360.0034742.134.29E-020.349jerabiliary atresia200.001750.009395.684.92E-020.349jerent-probp measurement200.001750.009935.684.92E-020.349jerent-probp measurement200.001750.009935.684.92E-020.349jere									_
complement C3 measurement410.0005820.0019853.413.15E-020.283immune_systemcomplement C4 measurement410.0005820.0014893.413.15E-020.283immune_systemhepatitis B infection310.0003490.0014894.263.46E-020.290immune_systeminfant body height520.008730.0024812.843.35E-020.290body_measurementkidney disease310.0051240.0084371.653.44E-020.290kidneymean corpuscular hemoglobin17100.005520.008331.613.54E-020.292nervous_systemsporadic amyotrophic lateral sclerosis18110.005520.0084371.653.44E-020.292nervous_systemmultiple myeloma1050.0025620.008331.613.54E-020.307cancerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseasenarcolepsy520.000320.0024812.664.22E-020.329brain_diseaseatopic eczema730.0016300.0034742.134.99E-020.349immune_systembiliary atresia200.0001750.009935.684.92E-020.349immune_systemeye measurement630.001750.009935.684.92E-020.349ipvereye	•								_
complement C4 measurement410.0005820.0019853.413.15E-020.283immune_systemhepatitis B infection310.0003490.0014894.263.46E-020.290immune_systeminfant body height520.0008730.0024812.843.35E-020.290body_measurementkidney disease310.0003490.0014894.263.46E-020.290bidodymean corpuscular hemoglobin17100.0051240.0084371.653.44E-020.292hervous_systemsporadic amyotrophic lateral sclerosis18110.0055320.0089331.613.54E-020.292hervous_systemmultiple myeloma1050.0025620.0049631.943.79E-020.307cancerconduct disorder1380.0012520.0024812.664.22E-020.329brain_diseasenarcolepsy520.0009320.0024812.664.22E-020.329brain_diseaseshort-term memory410.006410.0019853.104.21E-020.329brain_diseaseatopic eczema730.0016300.0034742.134.99E-020.349livereye measurement630.001750.0009935.684.92E-020.349greynt-probnp measurement200.001750.009935.684.92E-020.349greyresponse to bevaci									
hepatitis B infection310.0003490.0014894.263.46E-020.0290immune_systeminfant body height520.008730.0024812.843.35E-020.290body_measurementkidney disease310.003490.0014894.263.46E-020.290kidneymean corpuscular hemoglobin17100.0051240.0084371.653.44E-020.290bloodsporadic amyotrophic lateral sclerosis18110.005520.0089331.613.54E-020.292nervous_systemmultiple myeloma1050.0025620.0049631.943.79E-020.307cancerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseasenarcolepsy5520.0009320.0024812.664.22E-020.329brain_diseaseshort-term memory410.0006410.019853.104.21E-020.329brain_diseasebiliary atresia200.001750.009935.684.92E-020.349inmune_systembiliary atresia200.001750.009935.684.92E-020.349equent-probnp measurement200.0001750.009935.684.92E-020.349erdiovascularresponse to bevacizumab200.0001750.009935.684.92E-020.349drug_response		4							— •
kidney disease310.0003490.0014894.263.46E-020.290kidneymean corpuscular hemoglobin17100.0051240.0084371.653.44E-020.290bloodsporadic amyotrophic lateral sclerosis18110.0055320.0089331.613.54E-020.292nervous_systemmultiple myeloma1050.0025620.0049631.943.79E-020.307cancerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseasenarcolepsy520.009320.0024812.664.22E-020.329brain_diseaseshort-term memory410.006410.019853.104.21E-020.329brain_diseaseatopic eczema730.001750.009935.684.92E-020.349immune_systembiliary atresia200.001750.009935.684.92E-020.349eyent-probnp measurement200.001750.009935.684.92E-020.349cardiovascularresponse to bevacizumab200.0001750.009935.684.92E-020.349drug_response	hepatitis B infection	3	1	0.000349	0.001489	4.26	3.46E-02		
mean corpuscular hemoglobin17100.0051240.0084371.653.44E-020.290bloodsporadic amyotrophic lateral sclerosis18110.005520.0089331.613.54E-020.292nervous_systemmultiple myeloma1050.0025620.0049631.943.79E-020.307cancerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseasenarcolepsy5520.009320.0024812.664.22E-020.329brain_diseaseshort-term memory4410.006410.019853.104.21E-020.329brain_diseaseatopic eczema730.0016300.0034742.134.99E-020.349immune_systembiliary atresia200.001750.009935.684.92E-020.349eyent-probnp measurement200.001750.009935.684.92E-020.349cardiovascularresponse to bevacizumab200.0001750.009935.684.92E-020.349drug_response	infant body height	5	2	0.000873	0.002481	2.84	3.35E-02	0.290	body_measurement
sporadic amyotrophic lateral sclerosis 18 11 0.005532 0.008933 1.61 3.54E-02 0.292 nervous_system multiple myeloma 10 5 0.002562 0.004963 1.94 3.79E-02 0.307 cancer conduct disorder 13 8 0.003727 0.006452 1.73 4.27E-02 0.329 brain_disease narcolepsy 5 2 0.000322 0.002481 2.66 4.22E-02 0.329 brain_disease short-term memory 4 1 0.000451 0.001985 3.10 4.21E-02 0.329 brain_disease atopic eczema 7 3 0.001630 0.003474 2.13 4.99E-02 0.349 immune_system biliary atresia 2 0 0.00175 0.00093 5.68 4.92E-02 0.349 iver eye measurement 6 3 0.00175 0.0093 5.68 4.92E-02 0.349 erdiovascular response to bevacizumab 2 0									•
multiple myeloma1050.0025620.0049631.943.79E-020.307cancerconduct disorder1380.0037270.0064521.734.27E-020.329brain_diseasenarcolepsy520.009320.0024812.664.22E-020.329brain_diseaseshort-term memory410.0006410.019853.104.21E-020.329brainatopic eczema730.0016300.0034742.134.99E-020.349immune_systembiliary atresia200.001750.009935.684.92E-020.349ivereye measurement630.001750.009935.684.92E-020.349eyent-probnp measurement200.0001750.009935.684.92E-020.349cardiovascularresponse to bevacizumab200.0001750.009935.684.92E-020.349drug_response									
conduct disorder 13 8 0.003727 0.006452 1.73 4.27E-02 0.329 brain_disease narcolepsy 5 2 0.00932 0.002481 2.66 4.22E-02 0.329 brain_disease short-term memory 4 1 0.000645 0.01985 3.10 4.21E-02 0.329 brain atopic eczema 7 3 0.001630 0.003474 2.13 4.99E-02 0.349 immune_system biliary atresia 2 0 0.00175 0.00993 5.68 4.92E-02 0.349 iver eye measurement 6 3 0.00175 0.00993 5.68 4.92E-02 0.349 eye nt-probnp measurement 2 0 0.000175 0.00993 5.68 4.92E-02 0.349 erdiovascular response to bevacizumab 2 0 0.000175 0.00993 5.68 4.92E-02 0.349 draiovascular									— ·
narcolepsy 5 2 0.00932 0.002481 2.66 4.22E-02 0.329 brain_disease short-term memory 4 1 0.000641 0.01985 3.10 4.21E-02 0.329 brain atopic eczema 7 3 0.001630 0.003474 2.13 4.99E-02 0.349 immune_system biliary atresia 2 0 0.00175 0.00093 5.68 4.92E-02 0.349 iver eye measurement 6 3 0.00175 0.00093 5.68 4.92E-02 0.349 eye nt-probnp measurement 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 eye response to bevacizumab 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 drug_response									
short-term memory 4 1 0.000641 0.001985 3.10 4.21E-02 0.329 brain atopic eczema 7 3 0.001630 0.003474 2.13 4.99E-02 0.349 immune_system biliary atresia 2 0 0.00175 0.00093 5.68 4.92E-02 0.349 iwer eye measurement 6 3 0.00175 0.002978 2.32 4.76E-02 0.349 eye nt-probnp measurement 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 eye response to bevacizumab 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 eye									-
atopic eczema 7 3 0.001630 0.003474 2.13 4.99E-02 0.349 immune_system biliary atresia 2 0 0.00175 0.00093 5.68 4.92E-02 0.349 liver eye measurement 6 3 0.001281 0.002978 2.32 4.76E-02 0.349 eye nt-probnp measurement 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 eye response to bevacizumab 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 cardiovascular									-
biliary atresia 2 0 0.000175 0.00093 5.68 4.92E-02 0.349 liver eye measurement 6 3 0.001281 0.002978 2.32 4.76E-02 0.349 eye nt-probnp measurement 2 0 0.000175 0.000993 5.68 4.92E-02 0.349 eye response to bevacizumab 2 0 0.000175 0.000993 5.68 4.92E-02 0.349 cardiovascular	-								
nt-probnp measurement 2 0 0.000175 0.000993 5.68 4.92E-02 0.349 cardiovascular response to bevacizumab 2 0 0.000175 0.000993 5.68 4.92E-02 0.349 cardiovascular		2	0	0.000175	0.000993		4.92E-02		
response to bevacizumab 2 0 0.000175 0.000993 5.68 4.92E-02 0.349 drug_response	eye measurement	6	3	0.001281	0.002978	2.32	4.76E-02	0.349	eye
τοοτη agenesis 2 0 0.000175 0.000993 5.68 4.92E-02 0.349 dental									
	tooth agenesis	1 2	0	0.000175	0.000993	5.68	4.92E-02	0.349	uentai

Aggregate		Observed	Expected	Expected	Observed			Adjusted P-	
Grammatical Class	GWAS Ontology Term	Peak Count	Peak Count	Frequency	Frequency	Freq FC	Raw P-Value	Value (fdr)	Category
	crohn's disease	25	11	0.012287	0.028027	2.28	1.69E-04	0.014	Immune System
	esophageal squamous cell carcinoma	5	1	0.000582	0.005605	9.63	2.03E-04	0.014	Cancer
	inflammatory bowel disease	19	7	0.007628	0.021300	2.79	8.39E-05	0.011	Immune System
MCKG	multiple sclerosis	23	11	0.012170	0.025785	2.12	8.11E-04	0.041	Immune System
Werd	response to irinotecan	5	0	0.000524	0.005605	10.70	1.25E-04	0.013	drug_response
	schizophrenia	37	18	0.020439	0.041480	2.03	6.06E-05	0.011	brain_disease
	seasonal allergic rhinitis	10	2	0.002155	0.011211	5.20	3.24E-05	0.011	Immune System
	ulcerative colitis	17	7	0.007628	0.019058	2.50	6.70E-04		Immune System
	blood metabolite measurement	19	6	0.012694	0.040860	3.22	1.18E-05	1.74E-03	Blood
	erythrocyte measurement	9	1	0.002620	0.019355	7.39	5.17E-06	1.52E-03	Blood
	inflammatory bowel disease	13	4	0.007628	0.027957	3.66	7.91E-05	5.64E-03	Immune System
Three cell	mean corpuscular hemoglobin	9	2	0.005124	0.019355	3.78	7.86E-04	0.039	Blood
	metabolic syndrome	10	2	0.003901	0.021505	5.51	1.94E-05	1.90E-03	other_metabolic_disorder
	psoriasis	6	1	0.002387	0.012903	5.40	9.93E-04	0.042	Immune System
	systemic scleroderma	7	1	0.002213	0.015054	6.80	9.59E-05	5.64E-03	Immune System
Two cell miixed	immune system disease	4	0	0.001165	0.017391	14.93	1.69E-04	0.035	Immune System
	self reported educational attainment	6	1	0.004076	0.026087	6.40	4.06E-04	0.042	brain
Human specific	anti-Heliobacter pylori serum IgG measurement	3	0	0.000116	0.009063	77.82	9.19E-06	2.50E-03	Immune System
	erythrocyte measurement	6	1	0.002620	0.018127	6.92	2.74E-04	0.025	Blood
	platelet count	8	2	0.005357	0.024169	4.51	4.84E-04	0.033	Blood
	systemic lupus erythematosus	11	3	0.007861	0.033233	4.23	7.91E-05	0.011	Immune System

		Observed	Expected	Expected	Observed			Adjusted P-	
Grammatical Class	GWAS Ontology Term	Peak Count	Peak Count	Frequency	Frequency	Freq FC	Raw P-Value	Value (fdr)	Category
	colorectal cancer	1	0	0.004950	0.333333	67.35	0.015	0.022	cancer
	immune system disease	1	0	0.001165	0.333333	286.22	3.49E-03	0.022	immune_system
M	mean corpuscular hemoglobin	1	0	0.005124	0.333333	65.05	0.015	0.022	blood
	mean corpuscular volume	1	0	0.004134	0.333333	80.62	0.012	0.022	blood
	platelet count	1	0	0.005357	0.333333	62.22	0.016	0.022	blood
С	mean platelet volume	1	0	0.003086	0.333333	108.01	9.23E-03	0.028	blood
К									
	alcohol drinking	3	0	0.004542	0.060000	13.21	1.57E-03	0.037	behavior
G	anti-Heliobacter pylori serum IgG measurement	3	0	0.000116	0.060000	515.19	3.08E-08	2.93E-06	immune_system
9	celiac disease	3	0	0.003901	0.060000	15.38	1.01E-03	0.032	gut
	seasonal allergic rhinitis	3	0	0.002155	0.060000	27.85	1.82E-04	8.63E-03	immune_system
KG	total blood protein measurement	2	0	0.000408	0.032787	80.44	2.99E-04	0.044	blood
CG									
CIV.	immune system disease	4	0	0.001165	0.017391	14.93	1.69E-04	0.035	immune_system
СК	self reported educational attainment	6	1	0.004076	0.026087	6.40	4.06E-04	0.042	brain
MC									
MK									
	blood metabolite measurement	12	4	0.012694	0.038339	3.02	7.85E-04	0.032	blood
	colorectal cancer	7	2	0.004950	0.022364	4.52	1.07E-03	0.037	cancer
	crohn's disease	13	4	0.012287	0.041534	3.38	1.66E-04	0.010	immune_system
6146	erythrocyte measurement	7	1	0.002620	0.022364	8.53	2.30E-05	3.17E-03	blood
CKG	immune system disease	4	0	0.001165	0.012780	10.97	5.42E-04	0.026	immune_system
	inflammatory bowel disease	11	2	0.007628	0.035144	4.61	3.69E-05	3.17E-03	immune_system
	mean corpuscular hemoglobin	7	2	0.005124	0.022364	4.36	1.30E-03	0.040	blood
	metabolic syndrome	8	1	0.003901	0.025559	6.55	3.91E-05	3.17E-03	other_metabolic_disorder
MCG									
МСК									
MCKG	crohn's disease	25	11	0.012287	0.028027	2.28	1.69E-04	0.014	immune_system
	esophageal squamous cell carcinoma	5	1	0.000582	0.005605	9.63	2.03E-04	0.014	cancer
	inflammatory bowel disease	19	7	0.007628	0.021300	2.79	8.39E-05	0.011	immune_system
	multiple sclerosis	23	11	0.012170	0.025785	2.12	8.11E-04	0.041	immune_system
	response to irinotecan	5	0	0.000524	0.005605	10.70	1.25E-04	0.013	drug_response
	schizophrenia	37	18	0.020439	0.041480	2.03	6.06E-05	0.011	brain_disease
	seasonal allergic rhinitis	10	2	0.002155	0.011211	5.20	3.24E-05	0.011	immune_system
	ulcerative colitis	17	7	0.007628	0.019058	2.50	6.70E-04	0.039	immune_system